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Abstract  
Background:Clinical trials investigating the use of cannabinoid drugs for the treatment of intestinal 
inflammation are anticipated secondary to preclinical literature demonstrating efficacy in reducing 
inflammation.   
Methods:We systematically reviewed publications on the benefit of drugs targeting the endo-
cannabinoid system in intestinal inflammation.  We collated studies examining outcomes for meta-
analysis from EMBASE, MEDLINE and Pubmed until March 2017.  Quality was assessed according 
to mSTAIR and SRYCLE score. 
Results:From 2008 papers, 51 publications examining the effect of cannabinoid compounds on 
murine colitis, and two clinical studies were identified. 24 compounds were assessed across 71 
endpoints. Cannabidiol, a phytocannabinoid, was the most investigated drug. Macroscopic colitis 
severity (disease activity index - DAI) and myeloperoxidase activity (MPO) were assessed throughout 
publications and were meta-analysed using random effects models.  Cannabinoids reduced DAI in 
comparison with vehicle; SMD -1.36, 95% CI -1.62 to-1.09, I2=61%).  FAAH inhibitor URB597 had 
the largest effect size (SMD-4.43, 95% CI-6.32,-2.55), followed by the synthetic drug AM1241 (SMD 
–3.11, 95% CI -5.01, -1.22) and the endocannabinoid anandamide (SMD-3.03, 95% CI -4.89,-1.17, I2 
not assessed).  Cannabinoids reduced MPO in rodents compared to vehicle; SMD -1.26, 95% CI-1.54 
to -0.97, I2=48.1%.  Cannabigerol had the largest effect size (SMD -6.20, 95%CI-9.90, -2.50), 
followed by the synthetic CB1 agonist ACEA(SMD -3.15, 95%CI-4.75, -1.55) and synthetic CB1/2 
agonist WIN55,212-2(SMD-1.74, 95%CI-2.81, -0.67, I2=57%).  We found no evidence of reporting 
bias. No significant difference was found between the prophylactic and therapeutic use of cannabinoid 
drugs.  
Conclusions:There is abundant pre-clinical literature demonstrating the anti-inflammatory effects of 
cannabinoid drugs in inflammation of the gut. Larger randomised controlled-trials are warranted.  
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Table of abbreviations 
PPAR - Peroxisome Proliferator Activating Receptor 
TRPV1 - Transient receptor potential vanilloid 1 
AEA - Anandamide 
2-AG - 2-arachidonoyl glycerol 
PEA - Palmitoylethanolamide 
DNBS - Dinitrobenzene sulphonic acid 
OM - Oil of mustard 
TNBS - Trinitrobenzene sulphonic acid 
DSS - Dextran sulphate sodium 
CO - Croton oil 
THC - Δ9-Tetrahydrocannabinol 
CBD - Cannabidiol 
Ab-CBD - Abnormal cannabidiol 
CBG - Cannabigerol 
CBN - Cannabinol 
MMJ - Medicinal cannabis 
MPO - Myeloperoxidase 
DAI - Disease activity index 
IL-10 - Interleukin-10 
SMD - Standard mean difference 
CI - Confidence interval 
I.c. - Intracolonic 
p.o.- Oral  
i.v. - Intravenous 
p.r. - Per rectum 
s.c. - Subcutaneous  
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Introduction 
Inflammatory bowel disease (IBD) affects 200 per 100,000 adults in the United States and 400 per 
100,000 in the UK (1,2).  Major subtypes consist of Crohns disease and ulcerative colitis.  A 
definitive clinical treatment for these chronic relapsing diseases remains elusive, as currently no 
therapy exists to reverse the clinical pathology without a risk of significant side effects.  5-ASA 
agents, corticosteroids, anti-TNFα antibodies and other immunomodulatory drugs have all been 
shown to induce significant remission in IBD, but are associated with bone marrow suppression, 
opportunistic infection, infusion reactions and malignancy secondary to immunosuppression (3–5).  
The endocannabinoid system (ECS), consisting of multiple receptors and endogenous ligands, 
controls multiple homeostatic processes including gastrointestinal motility, hunger, perception of pain 
and immunity (6–10).  The receptors of the ECS consist of the classical CB1 and CB2 receptors, but 
also the orphan GPR55 receptor, peroxisome proliferator-activated receptors (PPARs) and transient 
receptor potential receptor vanilloid (TRPV) receptors.  These targets are all found on the cells of gut 
mucosa, submucosa, enteric nervous and immune systems.  Endocannabinoids, such as anandamide 
(AEA) and 2-arachiodoylglycerol (2-AG), are intercellular lipid signalling molecules derived on 
demand from membrane precursors (11). They are metabolised by fatty acid amide hydrolase (FAAH) 
as well as N-acyl ethanolamine-hydrolysing acid amidase (NAAA) in the case of AEA, and 
monoacylglycerol lipase (MAGL) in the case of 2-AG (12–14).   Palmitoylethanolamide (PEA), also 
metabolised by NAAA, has been shown to activate PPARα and may increase local concentrations of 
AEA or the affinity of AEA to the CB1 receptor and is therefore included as an atypical cannabinoid 
(15,16).  Phytocannabinoids include Δ-9 tetrahydrocannabinol (THC), cannabidiol (CBD), 
cannabigerol (CBG), cannibichromene (CBC) and up to 60 others and are isolated from Cannabis 
Sativa (11).  THC and CBD have found place in clinical practice in the treatment of childhood 
epilepsy and muscular spasticity in multiple sclerosis (17,18).  A growing collection of synthetic 
cannabinoid agonists have been derived possessing selective high affinity for the CB1, CB2, GPR55 
and TRPV1 receptors, and have been investigated pre-clinically for roles in gut motility, satiety and 
immunity (8). 
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Under inflammatory conditions CB1, CB2 and both PPARα and PPARγ expression increases on the 
submucosa and on adjacent immune cells, whereas GPR55 and TRPV1 expression decreases on the 
mucosa, but increases on enteric nervous tissue (19–21).  Levels of AEA, 2-AG and PEA are 
upregulated in vitro, and also in animal in vivo and human ex-vivo models of intestinal inflammation 
(22–24).  Early experimentation in murine models demonstrated cannabinoids prevent the onset of 
experimental murine colitis or reduced its severity (25).  Since these initial findings, many reports, 
including clinical trials, have now investigated the effect of cannabinoid ligands, or the effect of 
blockade of their metabolising enzymes, on inflammation of the gut.   
There is a significant amount of promising preclinical evidence for the use of cannabinoid agents in 
the treatment of colitis.  Within this study we aimed to gather all preclinical and clinical evidence for 
the use of these drugs in colitis, and where possible, perform meta-analyses across studies in order to 
assess the efficacy of cannabinoids for further clinical trials.  Where possible clinically relevant 
experimental endpoints were assessed.  
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Methods 
Search Strategy 
All studies evaluating the effect of cannabinoid drugs on inflammation of the colon were searched 
from March 1980 until March 2017 by two independent researchers in Medline, EMBASE and 
Pubmed.  Keywords included cannabidiol, tetrahydrocannabinol, anandamide, 2-AG, 
cannibichromene, cannabigerol, cannabinoid, cannabis sativa, colon, intestine, gut, inflammation, 
Crohns, ulcerative and colitis.  Names of synthetic cannabinoid agents were also included.  
References from included studies were searched by hand.  Pre-specified inclusion and exclusion 
criteria were used to prevent bias.  Experiments must have been be performed in the context of 
administration of cannabinoid drugs to inflammatory states of the colon in humans or animals, either 
experimental or due to endogenous disease (Crohns disease or ulcerative colitis).  In vitro studies or 
studies not examining the effect of cannabinoids in intestinal inflammation specifically, or studies 
using cannabinoid antagonists as a primary agent were excluded. A PRISMA checklist is included in 
the appendix. 
Data Acquisition 
The mode of colitis induction in preclinical studies was recorded in addition to the timing of 
cannabinoid application.  For the purposes of meta-analysis, data on the macroscopic or histological 
disease scores (disease activity index – DAI) and myeloperoxidase (MPO) activity were collected.  If 
the exact number of animals was not available, the lowest number of animals within the range given 
were used for the experimental group, and the highest number used for the control/vehicle group.  
Where studies reported the effects of more than one cannabinoid sharing a single control group for 
comparison, control group numbers were equally distributed between comparisons to avoid unit of 
analysis issues.  WebPlotDigitiser (version 3.11) was used to extract values from figures in published 
articles where no data values were given in the text.   
Quality 
Quality of included studies were assessed by two independent researchers to quantify risk of bias 
according to the six-point criteria developed by the Cochrane Collaboration risk of bias tool (26).  In 
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order to assess the quality of preclinical studies, the STAIR and Arrive preclinical assessment tools 
were adapted (27,28).   Each of the below were awarded one point: randomisation, assessor blinding, 
results replicated in a second species, dose-response experiments, results replicated in a second model 
of colitis, n=5 or greater in each group, the use of clinically relevant endpoint to assess response of 
colitis, definitive statement of animal numbers in each group,  a statement regarding the housing of 
animals and a statement describing the location and timing of animal experimentation (i.e. in animal 
housing or a separate cage, time of day etc), giving a highest possible score of 10. 
Data analysis 
Where possible, data were grouped into DAI and MPO activity, and subdivided by species and 
compound.  Data from each group were analysed as forest plots using Cochrane Review Manager 
Software (Review Manager 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014), and as funnel plots using Stat (Stat Corp. 2009 Stat Statistical Software: Release 
11. College Station, TX, USA).  Funnel plot asymmetry was tested using Egger’s linear regression 
test.  A P value of <0.05 was considered statistically significant.  As differing studies measured MPO 
activity and DAI using various scales, we present effect estimates as standardized mean differences 
(SMD) with 95% confidence intervals (CI). We used the following SMD values to assess results for 
clinical significance: < -0.5 small clinical significance, -0.5 to -0.8 moderate clinical significance and 
>-0.8 high clinical significance. Due to clinical heterogeneity between the various studies, a random-
effects model was used. We assessed statistical heterogeneity using the I2 statistic, with >50% 
regarded as evidence of statistical heterogeneity. We assessed the quality of evidence using the 
previously validated SYRCLE criteria, with studies graded out of 10 (29). Studies were weighted by 
sample size and statistical significance was set at a minimum of p<0.05.   
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Results 
Search results and study characteristics 
The search strategy returned 2008 results from which 199 relevant publications were identified.  From 
these, 53 publications comprising 106 experiments examining 35 compounds met the inclusion 
criteria (figure 1, table 1 and 2).  Thirty four studies were included in the meta-analysis.   
Forty-three publications studied the effects of cannabinoids on experimental murine colitis, 5 in rats, 
and 3 in both mice and rats.  Two clinical trials examined the effect of a cannabinoid (THC and CBD) 
in Crohns disease.  Within animal publications, 43 used caustic agents (Di-nitrobenzine sulphonic 
acid (DNBS), trinitrobenzene sulphonic acid (TNBS), oil of mustard (OM), dextran sulphate sodium 
(DSS) and croton oil (CO)) to induce colitis, 6 used intravenous or topical lipopolysaccharide, 2 
induced colonic inflammation using surgical arterial ligation or puncture of the colon and 1 induced 
colitis with interleukin-10 (IL-10) knock-down and DSS (figure 2A).  Across all publications, 
including clinical trials, 71 endpoints were examined to evaluate the effect of cannabinoid drugs on 
colitis.  Forty-nine publications (89 experiments) examined more than one endpoint.  Of these 
endpoints MPO and DAI were the most consistently used (34 and 26 studies respectively), and were 
therefore selected for meta-analysis. Incidence of endpoints is given in figure 2B.    
The effect of 7 phytocannabinoids were studied across 18 publications; cannabinol (CBN), CBD, 
THC, CBC, CBG, medicinal cannabis (MMJ) and abnormal CBD (Ab-CBD). 4 endocannabinoids 
were studied across 11 publications (PEA, ultramicronized PEA (uPEA), Arachidonyl-2'-
chloroethylamide (ACEA) and AEA), 15 synthetic cannabinoid agonists were studied across 22 
publications (AM841, Adelmidrol , HU210, CP55,940, WIN55,212-2, AM1241, JHW015, JWH133, 
βCaryophyllene, O-1602, HU308, αβ amyrin CID 16020046 compound 26 and SAB378), and 9 
compounds targeting the catabolism or transport of endogenous cannabinoids were studied across 13 
publications (ARN2508, PF-3845, compound 39, JZL184, AA5HT, VDM11, URB597,  AM9053, 
AM3506).  These compounds are delineated by class in table 1.  The degree of positivity or negativity 
of the outcomes of these studies are displayed in figure 2C.   Twenty-three studies investigated 
underlying receptor mechanisms using knock-out (KO) animals or receptor antagonists.   
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Of the 105 experiments comparing cannabinoids with vehicle or placebo, 67 (63.8%) favoured 
cannabinoids, 34 (32.3%) reported no difference, and 4 (3.8%) favoured vehicle.  Mice were used in 
89 experiments (68.5% of which favoured cannabinoids), rats in 14 (71.4% favoured cannabinoids), 
in 4 experiments both mice and rats were used showing no difference between cannabinoids and 
vehicle.  In the two clinical trials, no difference in primary outcome was found between the use of 
THC cigarettes or oral CBD and placebo.  11 of 14 publications (78.6%) using synthetic CB2 receptor 
agonists favoured cannabinoid use over vehicle, and a further 11 of 13 (84.6%) favoured using FAAH 
inhibitors over vehicle.  The outcome of all cannabinoids across publications is given in figure 2C.   
Two clinical trials examining the effect of CBD and THC in Crohns disease were found.  Naftali et al. 
(2013) conducted a placebo controlled study in Crohns disease patients, comparing THC 115mg 
inhaled alone with placebo.  Disease activity was compared between groups by means of validated 
questionnaire (Crohns disease activity index – CDAI) after 8 weeks of treatment.  A non-significant 
reduction in clinical disease remission as defined by the authors was found at the end of the study 
period, however a secondary endpoint of reduction in overall activity scores was found between 
groups (p=0.028).  In a second study, Naftali et al. (2017) compared oral CBD 10 mg p.o. twice daily 
with placebo in Crohns disease, using CDAI in an identical fashion.  No reduction in disease activity 
was detected between groups.  In both studies the authors measured changes in serum C-reactive 
protein (CRP), within both experimental and placebo groups CRP levels were below 5 units per ml at 
the end of the study periods.  Clinically, CRP levels greater than 5 units per ml are considered 
indicative of inflammatory disease.  Within both studies the combination of CBD and THC within a 
single study were not assessed. 
Of the 104 experiments where timing of drug administration of drug was stated, 37 administered 
cannabinoids therapeutically, of which 62.2% favoured cannabinoid treatment.   19 experiments 
administered cannabinoids prophylactically, of which 52.6% favoured cannabinoid treatment.  48 
experiments administered cannabinoids both prophylactically and therapeutically, of which 75% 
favoured cannabinoid treatment versus vehicle.  
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Meta-Analysis 
34 studies reported the same endpoints of disease activity index or myeloperoxidase activity allowing 
for meta-analysis.  Of the remaining studies heterogeneity of endpoints prevented further meta-
analysis. 
Crohns Disease Activity Index (CDAI). 
The use of two phytocannabinoids, THC or CBD, in two human studies were meta-analysed. 
Phytocannabinoid use decreased severity scores in comparison with placebo (mean difference (MD) -
74.97, 95% CI –229, 0.79, I2=75%.  Figure 3).  THC alone had a significant effect on reducing CDAI 
(MD-154.00, 95% CI -2.68.57, -44.43), whereas CBD alone did not (MD +4.00 95% CI -1.5.39, 
+113.39).     
Disease Activity Index (DAI) 
Thirty-four publications examined the effects of 25 cannabinoid drugs across 68 experiments, within 
mouse and rat models (total n = 948, n = 519 experimental vs 429 in control groups).   Cannabinoid 
drugs reduced DAI in comparison with vehicle; SMD -1.36, 95% CI -1.62 to-1.09, I2=61% (figure 4, 
table 3).  On subgroup analysis there was significant difference between drug subtypes (P<0.001).   
DAI was significantly reduced in mice (SMD -1.49, 95% CI -1.77 to -1.22; I2=61%).  Seven 
experiments within one publication examined the effects of cannabinoids on rat colitis (THC and 
CBD, both conducted in a dose response manner), but did not reach significance at any concentration; 
SMD -0.29, 95% CI -0.77 to 0.20, I2=0%.  SMD and confidence intervals for individual drugs on DAI 
are given in table 3.   
The largest effect size in DAI reduction was caused by an enzyme inhibitor: the FAAH inhibitor 
URB597 (SMD-4.43, 95% CI-6.32,-2.55).  The largest effect size of DAI reduction by an 
endocannabinoid was AEA (SMD-3.03, 95% CI -4.89,-1.17), the largest effect size of DAI reduction 
by a phytocannabinoid was CBD (SMD -0.56, 95% CI-0.97, -0.16, I2= 29%), and the largest synthetic 
cannabinoid effect size on DAI was AM1241 (SMD –3.11, 95% CI -5.01, -1.22).  SMD and 
confidence intervals of individual drugs on DAI are given in table 4.   Eighteen of twenty-five drugs 
had a large effect size, one had a moderate effect size, and six had no significant effect on DAI.   
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Myeloperoxidase Activity (MPO) 
Twenty-six publications investigated the effects of 21 cannabinoid drugs on MPO activity throughout 
57 individual experiments (total n = 757, n = 419 in experimental vs 338 in control groups). 
Cannabinoid drugs reduced MPO in comparison with vehicle; SMD -1.26, 95% CI-1.54 to -0.97, 
I2=48.1% (figure 5, table 4). Overall, there was significant heterogeneity between studies and there 
was significant subgroup difference (I2=48.1%, P<0.008).  MPO was significantly reduced in mice 
and rats (SMD -1.28, 95% CI -1.59 to -0.98 I2=61% and -1.06, 95% CI -1.99 to -0.13, I2=56% 
respectively).  
The largest effect size in MPO reduction was caused by the phytocannabinoid CBG (SMD -6.20, 95% 
CI -9.90 to -2.50, I2 not assessed).  The largest effect size by an endocannabinoid was PEA (SMD -
2.74, 95% CI -4.42, -1.06, I2=85%), the largest synthetic cannabinoid effect size on MPO was caused 
by ACEA (SMD -3.15, 95% CI -4.75, -1.55, I2 not assessed), and the largest effect size of any enzyme 
or transport inhibitor was AA5HT (SMD -2.27, 95% CI -4.05, -0.49, I2 not assessed).    SMD and 
confidence intervals of individual drugs on MPO activity are given in table 4.  Thirteen of 21 
cannabinoid drugs had a large clinical effect, the remaining of which had no significant effect on 
MPO. 
Time of administration 
From the 50 publications examining the effect of cannabinoids on murine colitis, 28 studies 
administered cannabinoid agents either simultaneously with colitis onset, or prophylactically.   17 
administered drugs between 15 minutes and 7 days after the onset of colitis.  Additionally 7 studies 
compared the benefit of prophylactic cannabinoid use to therapeutic, but did not find any difference in 
efficacy.  To investigate if timing of drug treatment affected DAI or MPO we compared study size-
weighted effect sizes (dependent variable) with time of administration (covariate) using meta-
regression.   We found that timing of drug administration weakly predicted effect size in reducing 
DAI and MPO, although this was of borderline statistical significance (P=0.09 R2=11% and P=0.055 
R2=41% respectively, figure 6 A and B).   
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Quality and risk of bias 
Of the 53 papers, 21 used randomisation in their design, 7 reported blinding of assessment, 5 
replicated their results in a second species, and 14 replicated their findings in a second model of 
colitis.  50 reported n≥5 in control and experimental groups.  15 publications reported specific 
numbers within groups.  All papers reported a clinically relevant endpoint.  Median study quality 
modified STAIR score was 5 out of 10 (mean 4.9, SD 2.29). Using meta-regression, higher quality 
scores predicted greater reductions in MPO activity (P=0.043 R2=65%, figure 6 D), but not in DAI 
(P=0.98 R2= 35%, Figure 6 C).     
The SYRCLE risk of bias score for each endpoint showed a trend to larger reduction in DAI in studies 
with a larger risk of bias (P=0.084 R2=69%, figure 6 E), but not MPO (P=0.345 R2=8%, figure 6F). 
Publication Bias  
Funnel plots comparing MPO activity and DAI were constructed and analysed statistically for bias.  
The presence of publication bias was not found in either group (MPO; Egger’s statistic P=0.570, 
figure 7A; DAI; Egger’s statistic P=0.274, figure 7B).   
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Discussion 
The aim of this study was to determine the efficacy of cannabinoid drugs in reducing gut 
inflammation to aid the design of further clinical studies.  We found 53 studies that examined this 
effect using endocannabinoids, phytocannabinoids, synthetic cannabinoids, and enzyme and reuptake 
inhibitors across multiple models of murine and human colitis. In both qualitative assessment and 
meta-analysis, these controlled studies demonstrate that the use of cannabinoid drugs are beneficial in 
reducing colonic inflammation in rats and mice, with unclear effects in human subjects.   
In animal studies, cannabinoids were shown to reduce inflammation both qualitatively, and at meta-
analysis. Across experiments included in this review CB2 agonists, FAAH inhibitors and CBD were 
the most widely studied and showed the greatest therapeutic benefit across all endpoints.  Subgroup 
analyses suggested that CBG caused the greatest reduction in MPO activity scores followed by 
synthetic CB1 agonist ACEA. However both agents were only studied within a single publication.  In 
the MPO analysis the most studied drug was CBD, with 157 animals across 7 publications, 
demonstrating a significant effect on MPO activity reduction.  Similarly, within DAI analysis CBD 
was again the most studied single drug including 181 animal across 6 publications.  Although CBD 
demonstrated a significant effect on DAI reduction, the largest reduction in DAI was caused by the 
FAAH antagonist URB597, studied in one publication.  There was statistical heterogeneity in both 
MPO and DAI analyses, which was partially accounted for by subgroup differences.  At meta-
regression, factors leading to subgroup differences were quality, timing and risk of bias. 
Receptor targets were explored in 23 publications using receptor-specific agonists or antagonists, and 
receptor knock-down.  In murine colitis, agonism of the CB1 or CB2 receptor brought about reduction 
in inflammation, and at subgroup analysis use of the synthetic CB1/CB2 agonists acting demonstrated 
the greatest reduction in disease scores and MPO activity.  In addition, agonism of the PPARα, 
GPR55 and GPR18 receptors also reduced inflammation of the colon.  The wide variation in the 
measured inflammatory endpoints across these studies prevented further meta-analysis.  Interestingly 
the use of the peripherally restricted synthetic agonist SAB378, which agonises both CB1 and CB2 
receptors, had no significant effect on either MPO activity or DAI.   This is in contrast to ex vivo 
explant human colonic data, which demonstrated that cannabinoid agonism with AEA or CBD was 
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beneficial in colonic mucosal inflammation, which were peripherally restricted by definition of the 
explant model (30,31).  Izzo et al. (9) found through receptor antagonism that the effect of CBN in 
preventing hypermobility caused by croton oil was mediated by CB1, but not CB2.   PEA was 
investigated by Capasso et al. (20,32) using two models of inflammation-induced hypermotility.  
Using receptor antagonists in both experiments Capasso et al. found that PEA, in an OM model, acted 
through CB1 but not CB2 or PPARα, but in a CO model PEA was still effective, but did not act 
through CB1 or CB2. This suggests that the mechanism by which PEA acts as an anti-inflammatory 
agent was not mediated by a single receptor, but by receptor co-dependence.   ACEA was investigated 
for receptor mechanism in two publications, both of which found ACEA dependent on CB1.  None of 
the reviewed studies investigated a mechanism of action for AEA in gut inflammation, however one 
ex vivo human study from Harvey et al. found that AEA prevented increased cytokine production in 
experimentally inflamed human mucosa was dependent on CB2, although the authors did not report 
antagonism of any other receptor (31).   
The specific mechanism by which manipulation of the cannabinoid system affects inflammation is not 
clear.  Esposito et al. (33) demonstrated that PEA brought about anti-inflammatory effects on enteric 
glial cells acting at toll-like receptor 4, suggesting that rather than acting at an epithelial mucosal 
level, acts at either at innate immune colonies or the enteric nervous system. This hypothesis as 
recently been evidence by a study demonstrating that both CBD and PEA do not act on the immune 
response of epithelial cells, but are likely to require the presence of these other cells types, acting 
through down regulation of NF-κβ (34), but is challenged by Cluny et al, demonstrating that 
peripherally restricted cannabinoids have a diminished effect on inflammation.  Nevertheless it is 
clear that the mechanism of action of cannabinoids does not simply lie at the epithelial level, but is 
likely to reside within the gut-brain axis.  
From the clinical literature we found two randomised placebo-controlled studies examining the effect 
of phytocannabinoids in humans.  Our analysis found no overall effect of THC or CBD on disease 
scores, however there was large statistical and clinical heterogeneity between these studies.  We found 
from meta-analysis that inhaled THC did have a beneficial effect on CDAI at 8 weeks, whereas CBD 
did not.  There may be several reasons for this heterogeneity, firstly in all groups, small cohort sizes 
 15 
were used which may have overestimated positive or negative effects in both studies, making 
meaningful conclusions regarding the use of CBD or THC in inflammatory bowel disease difficult.   
Secondly, within the Naftali et al. (2017) study, very low doses of CBD were utilized compared to the 
use of CBD in other clinical trials, which commonly used 600mg twice daily (35).  A recent trial in 
drug-resistant epilepsy used 20mg.kg-1 daily for 4 weeks, with a small number of participants 
experiencing side effects such as vomiting and diarrhoea (36).  It is likely that in adult males such 
10mg doses had no clinical effect on Crohns disease as insufficient plasma concentrations may have 
been reached due to the poor bioavailability of oral CBD.  A major flaw within the Naftali et al. 2013 
trial is that sham cigarettes contained cannabis sativa flowers in which active cannabinoids had been 
removed.  However, it is unlikely that other compounds present in cannabis (such as terpenes) which 
are known to have an anti-inflammatory effect had also been removed, which may have introduced 
positive bias into the study (37).  However, despite these drawbacks, the Naftali et al. 2013 trial 
demonstrated a significant reduction in pain and the use of steroid therapy, with increased sleep and 
satisfaction levels with THC use compared to placebo.  Although not included in this analysis, a study 
from Storr et al. (38) demonstrated that although cannabis use provided symptomatic relief  from 
Crohns disease, the risk of salvage surgery was increased within 6 months of use (odds ratio = 5.03, 
95% confidence interval = 1.45-17.46).  However these findings have not yet been supported from 
randomised, blinding controlled trials.  We may suggest, therefore, that phytocannabinoid use may be 
a future therapy in intestinal inflammation, although before firm conclusions are drawn, further 
clinical studies examining their effects be conducted at higher, therapeutic dosages with adequately 
powered cohort sizes.  As MMJ use in inflammatory bowel disease has been justified because of its 
effects on appetite and diarrhoea, studies may be designed to examine these quality of life-affecting 
endpoints directly.    
We found that most of the existing cannabinoid-gut research focusses on the therapeutic potential of 
CBD.  This is unsurprising as CBD is currently used clinically, is well tolerated, and has shown 
consistently positive results.  Nine studies found a positive, dose dependent effect on local 
inflammatory cytokine expression, COX2 activation, MPO activity, enteric glial cell activation and 
caspase-3 production, with associated improvements in macroscopic and histologic grades of 
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inflammation (39–46).  One study also showed that intraperitoneal CBD administration decreased 
oxidative-stress scores of peripheral lung and brain tissue following intestinal inflammation (47), 
adding to the existing evidence that CBD maintains the gut barrier during inflammation (48).  Despite 
being the most-studied drug, the mechanism by which CBD acts was not made clear by this review. 
One study by De Fillipis et al (44), found that hyper-motility caused by LPS administration in mice 
was reduced by CBD through a CB1 dependent mechanism.  Similarly, Capasso et al. in 2008 found 
that CBD prevented croton oil-induced hypermotility via CB1.  In vitro, de Fillipis et al. in 2011 
demonstrated that in human explant tissue S100B levels, as a marker of glial cell activation was 
decreased by CBD in a PPARγ dependent mechanism (although other antagonists were not 
investigated) (49).   
The timing of cannabinoid administration correlated with reduction in effect on colitis activity, 
although did not reach statistical significance.  There was a correlation between time of drug 
administration and effect size in both DAI and MPO reduction, with earlier administration of 
cannabinoids drugs producing a greater effect size, suggesting that in clinical trials cannabinoids may 
be used prophylactically and therapeutically. There is promise therefore that compounds targeting the 
endocannabinoid system may be able to not only prevent colonic inflammation, but treat established 
intestinal inflammatory conditions.  As it is not clear if cannabinoids are more effective when treating 
new-onset or established intestinal inflammation, further study designs should investigate this 
endpoint specifically. 
One important potential area for research is the combination of cannabinoid drugs with existing 
treatments for inflammatory bowel disease.  In clinical practice it is common to treat patients with 
acute severe Crohns and ulcerative colitis with combination of agents, such as antibiotic, anti-TNFα, 
and corticosteroid therapy.  One study compared the efficacy of CBD and THC with that of 
sulphasalazine, a 5-ASA, a drug commonly used in clinical practice (45).   Although in this study 
CBD and THC efficacy were comparable to that of sulphasalazine, the authors did not examine for the 
potential additive or subtractive effect of these agents in the context of colitis.   
The findings of this study are limited by several factors typically seen in meta-analyses and systematic 
reviews. We found significant heterogeneity between sub-groups in both DAI and MPO analyses, and 
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suggested that 11% and 41% of this was due to the difference in time of administration in terms of 
changes in DAI and MPO respectively.  Additionally we found a high risk of bias study design, and 
median study quality to be relatively low.  Meta-regression demonstrated these factors significantly 
correlated with study outcomes.  Although we did not analyse for differences between scoring 
systems and mode of colitis, these factors may have also contributed to heterogeneity and influenced 
outcome.  We sought to overcome this variability between scoring systems with random effects 
analysis.  Additionally within this review we have examined the effect of cannabinoid drugs en mass, 
which may have affected the overall outcome of meta-analyses.  It is possible that some articles may 
have not been identified in initial searches, or conference abstracts missed from the search period.  
Lastly, where control groups were compared to multiple experimental groups within the same set of 
experiments variance and SMD may be exaggerated, leading to further bias. 
In conclusion, we have shown in this systematic review and meta-analysis that cannabinoid drugs are 
beneficial in treating experimentally-induced murine models of colitis.  These positive findings 
support the development of further human clinical trials.  Current literature converges on CBD, and in 
order to avoid research bias the effect of all cannabinoid drugs, including the large number of 
currently un-investigated phytocannabinoid drugs, should also be investigated.  
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Figure 1. Record identification process 
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Figure 2. Positive, negative and neutral outcomes of cannabinoid treatment across modes of 
inflammation (A).  Incidence of endpoints across all experiments comparing cannabinoid treatment 
with control (B). The effect of cannabinoid drugs compared to control across all endpoints expressed 
as primary drug investigated (C). 
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Figure 3.  Forest plot of the effects of cannabinoid treatment on Crohns Disease, assessed by 
reduction in CDAI in human studies.  
Study or Subgroup
Naftali 2003 THC 115mg INH, 8 wks
Naftali 2017 CBD 10mg p.o. BD 8 weeks
Total (95% CI)
Heterogeneity: Tau² = 9361.92; Chi² = 4.00, df = 1 (P = 0.05); I² = 75%
Test for overall effect: Z = 0.95 (P = 0.34)
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Figure 4. Forest plot of the effects of cannabinoid treatment on Disease Activity Score subdivided by drug type. Time of administration in relation to onset 
of colitis is given where 'p' represents prophylactic administration, and ’t’ represents therapeutic administration. 
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Study or Subgroup
1.2.1 PEA
Impellizzeri 2015 PEA 10mg/kg i.p. DNBS (t)
Esposito 2014 PEA 10mg/kg i.p. DSS (t)
Borrelli 2014 PEA 1mg/kg p.o. DNBS (t)
Borrelli 2014 PEA 1mg/kg i.p. DNBS (t)
Esposito 2014 PEA 2mg/kg i.p. DSS (t)
Alhouayek 2015 PEA 10mg/kg i.p. DSS (p)
Alhouayek 2015 PEA 10mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 3.94; Chi² = 39.60, df = 6 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.2 SAB378
Cluny 2010 SAB378 1mg/kg i.p.TNBS (p)
Cluny 2010 SAB378 0.1mg/kg i.p. TNBS (p)
Cluny 2010 SAB378 1mg/kg i.p. DSS (t)
Cluny 2010 SAB378 0.1mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
1.2.3 βCaryophyllene
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (t)
Bento 2011 βCaryophyllene 12.5mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 25mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.90; Chi² = 7.49, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.04 (P = 0.04)
1.2.4 CBG
Borrelli 2013 CBG 30mg/kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.28 (P = 0.001)
1.2.5 WIN 55212-2
Feng 2016 WIN55,212 5mg/kg i.p. DSS (t)
Li 2013 WIN55212-2 5mg/kg i.p. DSS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. TNBS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.68; Chi² = 7.05, df = 3 (P = 0.07); I² = 57%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.6 Ademidrol
Cordaro 2016 Ademidrol 10mg/kg p.o DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.63 (P = 0.009)
1.2.9 AA5HT
D'Argenio 2006 AA5HT10mg/kg s.c DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.50 (P = 0.01)
1.2.10 VDM115
D'Argenio 2006 VDM11 5mg/kg s.c. DNBS (t)
Storr 2008 VDM11 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.06; Chi² = 2.42, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 2.07 (P = 0.04)
1.2.11 AM841
Fichna 2014 AM841 1mg/kg i.p. DSS (p)
Fichna 2014 AM841 1mg/kg i.p. TNBS (p)
Fichna 2014 AM841 0.1mg/kg i.p. DSS (p)
Fichna 2014 AM841 0.01mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.74; Chi² = 6.57, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 2.66 (P = 0.008)
1.2.12 ACEA
Kimball 2006 ACEA 10 mg/kg i.p.OM (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.86 (P = 0.0001)
1.2.13 CBD
Pagano 2016 CBD 30mg/kg i.p. DNBS (t)
Pagano 2016 CBD 60mg/kg p.o. DNBS (t)
Jamontt 2010 CBD 20mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 10mg/kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.r. TNBS (p)
Krohn 2016 abCBD 5mg/kg i.p. TNBS (t)
Schicho 2012 CBD 10mg.kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.o. TNBS (p)
Jamontt 2010 CBD 15mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.33, df = 9 (P = 0.50); I² = 0%
Test for overall effect: Z = 5.47 (P < 0.00001)
1.2.14 HU210
Massa 2004 HU210 0.05mg/kg i.p. DNBS (p)
Lin 2017 HU210 0.05mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
Test for overall effect: Z = 1.44 (P = 0.15)
1.2.15 CBC
Romano 2013 CBC 1mg.kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.80 (P = 0.005)
1.2.16 PF3745
Salaga 2014 PF3845 5mg/kg p.o.  TNBS (p)
Salaga 2014 PF3845 5mg.kg i.c. TNBS (p)
Salaga 2014 PF3845 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.31; Chi² = 10.40, df = 2 (P = 0.006); I² = 81%
Test for overall effect: Z = 0.16 (P = 0.87)
1.2.17 O-1602
Schicho 2011 O-1602 5mg/kg i.p. TNBS (p)
Schicho 2011 O-1602 5mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)
1.2.18 CID16020046
Stancic 2015 CID16020046 20mg/kg i.p. TNBS (p)
Stancic 2015 CID16020046 20mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.63 (P = 0.0003)
1.2.19 URB597
Storr 2008 URB597 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
1.2.20 AM1241
Storr 2009 AM1241 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
1.2.21 JWH133
Storr 2009 JWH133 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)
1.2.22 THC
Jamontt 2010 THC 10mg/kg i.p. TNBS (p)
Jamontt 2010 THC 20mg/kg i.p. TNBS (p)
Jamontt 2010 THC 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 4.11; Chi² = 9.99, df = 2 (P = 0.007); I² = 80%
Test for overall effect: Z = 1.07 (P = 0.28)
1.2.24 αβ Amyrin
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (p)
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Heterogeneity: Tau² = 0.66; Chi² = 139.42, df = 56 (P < 0.00001); I² = 60%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Chi² = 38.51, df = 20 (P = 0.008), I² = 48.1%
Mean
40.91
7.8
34.4
39.19
11.9
43.14
116.4
44.5
77.85
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116.04
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32.8
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35.2
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17.2
16.15
18.43
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44.9
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1.74
33.14
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86.36
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SD
6.7357
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28.14
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19.0066
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13.2
0.5814
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21.8197
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4.9749
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9.1679
0.4164
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29.1297
48.1964
35.3553
33.541
16.7705
69.2207
53.1315
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49.6407
39.0323
0.3648
0.2449
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0.8944
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Total
10
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7
8
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5
5
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28
8
8
5
5
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8
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6
6
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5
5
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68.69
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17.9
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100
1.218
1.218
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68.966
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184.3
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47.45
39.43
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9.03
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-1.67 [-2.72, -0.62]
0.25 [-0.63, 1.13]
-2.74 [-4.42, -1.06]
-0.72 [-2.03, 0.58]
-0.29 [-1.54, 0.96]
-0.13 [-1.37, 1.11]
0.13 [-1.07, 1.34]
-0.23 [-0.86, 0.39]
-3.07 [-5.20, -0.94]
-2.16 [-3.90, -0.42]
-0.43 [-1.69, 0.84]
-0.26 [-1.51, 0.98]
-1.26 [-2.48, -0.05]
-6.20 [-9.90, -2.50]
-6.20 [-9.90, -2.50]
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-3.15 [-4.75, -1.55]
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-0.99 [-1.94, -0.05]
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-1.35 [-2.55, -0.15]
-0.33 [-1.32, 0.66]
1.29 [0.18, 2.40]
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-1.73 [-3.31, -0.16]
-1.68 [-3.23, -0.12]
-1.70 [-2.81, -0.60]
-1.08 [-1.88, -0.28]
-1.01 [-1.80, -0.22]
-1.04 [-1.61, -0.48]
-1.00 [-2.06, 0.06]
-1.00 [-2.06, 0.06]
-0.96 [-2.31, 0.39]
-0.96 [-2.31, 0.39]
-0.98 [-2.04, 0.07]
-0.98 [-2.04, 0.07]
-3.22 [-5.33, -1.11]
-2.10 [-4.26, 0.06]
0.92 [-0.80, 2.64]
-1.40 [-3.97, 1.17]
-0.42 [-1.88, 1.04]
-0.33 [-1.99, 1.33]
-0.38 [-1.48, 0.71]
-1.26 [-1.54, -0.97]
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Study or Subgroup
1.2.1 PEA
Impellizzeri 2015 PEA 10mg/kg i.p. DNBS (t)
Esposito 2014 PEA 10mg/kg i.p. DSS (t)
Borrelli 2014 PEA 1mg/kg p.o. DNBS (t)
Borrelli 2014 PEA 1mg/kg i.p. DNBS (t)
Esposito 2014 PEA 2mg/kg i.p. DSS (t)
Alhouayek 2015 PEA 10mg/kg i.p. DSS (p)
Alhouayek 2015 PEA 10mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 3.94; Chi² = 39.60, df = 6 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.2 SAB378
Cluny 2010 SAB378 1mg/kg i.p.TNBS (p)
Cluny 2010 SAB378 0.1mg/kg i.p. TNBS (p)
Cluny 2010 SAB378 1mg/kg i.p. DSS (t)
Cluny 2010 SAB378 0.1mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
1.2.3 βCaryophyllene
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (t)
Bento 2011 βCaryophyllene 12.5mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 25mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.90; Chi² = 7.49, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.04 (P = 0.04)
1.2.4 CBG
Borrelli 2013 CBG 30mg/kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.28 (P = 0.001)
1.2.5 WIN 55212-2
Feng 2016 WIN55,212 5mg/kg i.p. DSS (t)
Li 2013 WIN55212-2 5mg/kg i.p. DSS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. TNBS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.68; Chi² = 7.05, df = 3 (P = 0.07); I² = 57%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.6 Ademidrol
Cordaro 2016 Ademidrol 10mg/kg p.o DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.63 (P = 0.009)
1.2.9 AA5HT
D'Argenio 2006 AA5HT10mg/kg s.c DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.50 (P = 0.01)
1.2.10 VDM115
D'Argenio 2006 VDM11 5mg/kg s.c. DNBS (t)
Storr 2008 VDM11 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.06; Chi² = 2.42, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 2.07 (P = 0.04)
1.2.11 AM841
Fichna 2014 AM841 1mg/kg i.p. DSS (p)
Fichna 2014 AM841 1mg/kg i.p. TNBS (p)
Fichna 2014 AM841 0.1mg/kg i.p. DSS (p)
Fichna 2014 AM841 0.01mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.74; Chi² = 6.57, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 2.66 (P = 0.008)
1.2.12 ACEA
Kimball 2006 ACEA 10 mg/kg i.p.OM (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.86 (P = 0.0001)
1.2.13 CBD
Pagano 2016 CBD 30mg/kg i.p. DNBS (t)
Pagano 2016 CBD 60mg/kg p.o. DNBS (t)
Jamontt 2010 CBD 20mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 10mg/kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.r. TNBS (p)
Krohn 2016 abCBD 5mg/kg i.p. TNBS (t)
Schicho 2012 CBD 10mg.kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.o. TNBS (p)
Jamontt 2010 CBD 15mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.33, df = 9 (P = 0.50); I² = 0%
Test for overall effect: Z = 5.47 (P < 0.00001)
1.2.14 HU210
Massa 2004 HU210 0.05mg/kg i.p. DNBS (p)
Lin 2017 HU210 0.05mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
Test for overall effect: Z = 1.44 (P = 0.15)
1.2.15 CBC
Romano 2013 CBC 1mg.kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.80 (P = 0.005)
1.2.16 PF3745
Salaga 2014 PF3845 5mg/kg p.o.  TNBS (p)
Salaga 2014 PF3845 5mg.kg i.c. TNBS (p)
Salaga 2014 PF3845 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.31; Chi² = 10.40, df = 2 (P = 0.006); I² = 81%
Test for overall effect: Z = 0.16 (P = 0.87)
1.2.17 O-1602
Schicho 2011 O-1602 5mg/kg i.p. TNBS (p)
Schicho 2011 O-1602 5mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)
1.2.18 CID16020046
Stancic 2015 CID16020046 20mg/kg i.p. TNBS (p)
Stancic 2015 CID16020046 20mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.63 (P = 0.0003)
1.2.19 URB597
Storr 2008 URB597 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
1.2.20 AM1241
Storr 2009 AM1241 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
1.2.21 JWH133
Storr 2009 JWH133 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)
1.2.22 THC
Jamontt 2010 THC 10mg/kg i.p. TNBS (p)
Jamontt 2010 THC 20mg/kg i.p. TNBS (p)
Jamontt 2010 THC 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 4.11; Chi² = 9.99, df = 2 (P = 0.007); I² = 80%
Test for overall effect: Z = 1.07 (P = 0.28)
1.2.24 αβ Amyrin
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (p)
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Heterogeneity: Tau² = 0.66; Chi² = 139.42, df = 56 (P < 0.00001); I² = 60%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Chi² = 38.51, df = 20 (P = 0.008), I² = 48.1%
Mean
40.91
7.8
34.4
39.19
11.9
43.14
116.4
44.5
77.85
85.7
116.04
0.4438
0.68
0.69
0.615
6.279
47.2
45.3
32.8
24.4
786
35.2
16
17.2
16.15
18.43
27.14
44.9
5.7
4.62
5.7
2.87
4.6
69.4
60.03
80.5
70.83
4.1
5.5
2.9
1.74
33.14
61.01
86.36
142
21.98
67.06
313.5
172
30.5
32.9
25
1.74
2.21
4.37
0.16
0.43
SD
6.7357
1.4207
5.6
28.14
2.9394
33.2039
84.3379
39.802
37.7895
56.1253
102.1062
0.208
0.2012
1.5652
2.9069
3.1752
23.1931
20.9304
19.6774
20.3482
388.9602
19.0066
15.4289
9.051
10.748
7.3539
8.8813
27.4357
13.2
0.5814
1.7889
1.3266
0.3317
21.8197
32.5715
17.7088
50.7444
4.9749
3.6483
9.1679
0.4164
7.2001
29.1297
48.1964
35.3553
33.541
16.7705
69.2207
53.1315
6.5054
49.6407
39.0323
0.3648
0.2449
0.9798
0.8944
0.246
Total
10
6
4
4
6
10
10
50
5
5
5
8
23
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
8
8
8
8
32
9
9
5
5
11
11
10
10
10
11
11
11
95
5
6
11
5
5
7
8
8
23
5
5
10
14
14
28
8
8
5
5
8
8
11
6
6
23
5
5
10
419
Mean
100
17.9
68.69
100
17.9
100
100
100
100
100
100
1.218
1.218
1.218
1.218
68.966
185.25
184.3
100
100
1,428
100
100
100.1
47.45
39.43
47.45
47.45
199
6.06
9.03
6.05
6.05
105.55
100
106.9
101.38
6.05
6.05
100
3.21
67.64
100
100
100
100
100.31
435
428.37
100
100
100
3.33
3.33
3.33
0.719
0.719
SD
9.8284
1.7321
11.2
18.4
1.7321
31.939
26.2469
89.6663
89.66
127.523
127.52
0.246
0.246
0.246
0.246
12.522
62.2254
66.468
89.6663
128.1267
528.1004
31.0813
31.0813
92.7724
14.99
9.8995
14.99
14.99
87.3098
0.5143
0.2236
2.3548
2.3548
43.9557
43.6394
35.1013
18.5731
2.3548
2.3548
103.4489
8.0833
12.9692
24.8701
25.7104
25.4558
46.7338
19.0066
138.4413
344.2325
92.7724
74.4611
94.4695
0.995
0.995
0.995
1.5588
1.5588
Total
10
3
4
4
3
10
10
44
5
5
5
4
19
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
2
8
3
3
16
7
7
5
5
3
3
10
10
10
11
3
2
62
7
6
13
5
5
7
8
8
23
5
5
10
14
14
28
8
8
5
5
8
8
2
2
2
6
3
2
5
338
Weight
0.9%
0.5%
0.8%
1.2%
1.4%
2.2%
2.5%
9.5%
1.9%
2.0%
2.0%
2.0%
7.9%
1.2%
1.5%
2.0%
2.0%
6.6%
0.5%
0.5%
1.7%
1.8%
1.9%
1.9%
7.3%
2.3%
2.3%
1.4%
1.4%
1.1%
2.2%
3.3%
1.2%
1.9%
1.6%
1.9%
6.5%
1.6%
1.6%
1.4%
1.4%
1.7%
1.8%
2.4%
2.4%
2.4%
2.5%
1.9%
1.7%
19.5%
2.0%
2.1%
4.1%
1.2%
1.2%
2.0%
2.3%
2.2%
6.5%
1.6%
1.6%
3.3%
2.6%
2.6%
5.1%
2.2%
2.2%
1.9%
1.9%
2.2%
2.2%
1.2%
1.1%
1.5%
3.8%
1.7%
1.5%
3.3%
100.0%
IV, Random, 95% CI
-6.72 [-9.20, -4.23]
-5.92 [-9.82, -2.02]
-3.37 [-6.07, -0.67]
-2.22 [-4.29, -0.16]
-2.01 [-3.87, -0.15]
-1.67 [-2.72, -0.62]
0.25 [-0.63, 1.13]
-2.74 [-4.42, -1.06]
-0.72 [-2.03, 0.58]
-0.29 [-1.54, 0.96]
-0.13 [-1.37, 1.11]
0.13 [-1.07, 1.34]
-0.23 [-0.86, 0.39]
-3.07 [-5.20, -0.94]
-2.16 [-3.90, -0.42]
-0.43 [-1.69, 0.84]
-0.26 [-1.51, 0.98]
-1.26 [-2.48, -0.05]
-6.20 [-9.90, -2.50]
-6.20 [-9.90, -2.50]
-2.78 [-4.26, -1.30]
-2.67 [-4.11, -1.22]
-0.94 [-2.28, 0.41]
-0.74 [-2.05, 0.56]
-1.74 [-2.81, -0.67]
-1.33 [-2.31, -0.34]
-1.33 [-2.31, -0.34]
-2.27 [-4.05, -0.49]
-2.27 [-4.05, -0.49]
-3.09 [-5.23, -0.96]
-1.19 [-2.28, -0.10]
-1.91 [-3.72, -0.10]
-2.49 [-4.58, -0.40]
-2.28 [-3.61, -0.94]
-1.76 [-3.37, -0.15]
-0.09 [-1.42, 1.24]
-1.56 [-2.71, -0.41]
-3.15 [-4.75, -1.55]
-3.15 [-4.75, -1.55]
-2.37 [-4.19, -0.55]
-2.36 [-4.18, -0.54]
-1.93 [-3.45, -0.40]
-1.35 [-2.75, 0.06]
-1.00 [-1.94, -0.06]
-0.99 [-1.94, -0.05]
-0.91 [-1.84, 0.02]
-0.77 [-1.64, 0.10]
-0.39 [-1.68, 0.89]
-0.14 [-1.65, 1.36]
-1.03 [-1.40, -0.66]
-1.12 [-2.39, 0.15]
-0.24 [-1.37, 0.90]
-0.63 [-1.48, 0.23]
-2.97 [-5.05, -0.89]
-2.97 [-5.05, -0.89]
-1.35 [-2.55, -0.15]
-0.33 [-1.32, 0.66]
1.29 [0.18, 2.40]
-0.12 [-1.56, 1.32]
-1.73 [-3.31, -0.16]
-1.68 [-3.23, -0.12]
-1.70 [-2.81, -0.60]
-1.08 [-1.88, -0.28]
-1.01 [-1.80, -0.22]
-1.04 [-1.61, -0.48]
-1.00 [-2.06, 0.06]
-1.00 [-2.06, 0.06]
-0.96 [-2.31, 0.39]
-0.96 [-2.31, 0.39]
-0.98 [-2.04, 0.07]
-0.98 [-2.04, 0.07]
-3.22 [-5.33, -1.11]
-2.10 [-4.26, 0.06]
0.92 [-0.80, 2.64]
-1.40 [-3.97, 1.17]
-0.42 [-1.88, 1.04]
-0.33 [-1.99, 1.33]
-0.38 [-1.48, 0.71]
-1.26 [-1.54, -0.97]
Experimental Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours [experimental] Favours [control]
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Study or Subgroup
1.2.1 PEA
Impellizzeri 2015 PEA 10mg/kg i.p. DNBS (t)
Esposito 2014 PEA 10mg/kg i.p. DSS (t)
Borrelli 2014 PEA 1mg/kg p.o. DNBS (t)
Borrelli 2014 PEA 1mg/kg i.p. DNBS (t)
Esposito 2014 PEA 2mg/kg i.p. DSS (t)
Alhouayek 2015 PEA 10mg/kg i.p. DSS (p)
Alhouayek 2015 PEA 10mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 3.94; Chi² = 39.60, df = 6 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.2 SAB378
Cluny 2010 SAB378 1mg/kg i.p.TNBS (p)
Cluny 2010 SAB378 0.1mg/kg i.p. TNBS (p)
Cluny 2010 SAB378 1mg/kg i.p. DSS (t)
Cluny 2010 SAB378 0.1mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
1.2.3 βCaryophyllene
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (t)
Bento 2011 βCaryophyllene 12.5mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 25mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.90; Chi² = 7.49, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.04 (P = 0.04)
1.2.4 CBG
Borrelli 2013 CBG 30mg/kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.28 (P = 0.001)
1.2.5 WIN 55212-2
Feng 2016 WIN55,212 5mg/kg i.p. DSS (t)
Li 2013 WIN55212-2 5mg/kg i.p. DSS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. TNBS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.68; Chi² = 7.05, df = 3 (P = 0.07); I² = 57%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.6 Ademidrol
Cordaro 2016 Ademidrol 10mg/kg p.o DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.63 (P = 0.009)
1.2.9 AA5HT
D'Argenio 2006 AA5HT10mg/kg s.c DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.50 (P = 0.01)
1.2.10 VDM115
D'Argenio 2006 VDM11 5mg/kg s.c. DNBS (t)
Storr 2008 VDM11 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.06; Chi² = 2.42, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 2.07 (P = 0.04)
1.2.11 AM841
Fichna 2014 AM841 1mg/kg i.p. DSS (p)
Fichna 2014 AM841 1mg/kg i.p. TNBS (p)
Fichna 2014 AM841 0.1mg/kg i.p. DSS (p)
Fichna 2014 AM841 0.01mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.74; Chi² = 6.57, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 2.66 (P = 0.008)
1.2.12 ACEA
Kimball 2006 ACEA 10 mg/kg i.p.OM (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.86 (P = 0.0001)
1.2.13 CBD
Pagano 2016 CBD 30mg/kg i.p. DNBS (t)
Pagano 2016 CBD 60mg/kg p.o. DNBS (t)
Jamontt 2010 CBD 20mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 10mg/kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.r. TNBS (p)
Krohn 2016 abCBD 5mg/kg i.p. TNBS (t)
Schicho 2012 CBD 10mg.kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.o. TNBS (p)
Jamontt 2010 CBD 15mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.33, df = 9 (P = 0.50); I² = 0%
Test for overall effect: Z = 5.47 (P < 0.00001)
1.2.14 HU210
Massa 2004 HU210 0.05mg/kg i.p. DNBS (p)
Lin 2017 HU210 0.05mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
Test for overall effect: Z = 1.44 (P = 0.15)
1.2.15 CBC
Romano 2013 CBC 1mg.kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.80 (P = 0.005)
1.2.16 PF3745
Salaga 2014 PF3845 5mg/kg p.o.  TNBS (p)
Salaga 2014 PF3845 5mg.kg i.c. TNBS (p)
Salaga 2014 PF3845 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.31; Chi² = 10.40, df = 2 (P = 0.006); I² = 81%
Test for overall effect: Z = 0.16 (P = 0.87)
1.2.17 O-1602
Schicho 2011 O-1602 5mg/kg i.p. TNBS (p)
Schicho 2011 O-1602 5mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)
1.2.18 CID16020046
Stancic 2015 CID16020046 20mg/kg i.p. TNBS (p)
Stancic 2015 CID16020046 20mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.63 (P = 0.0003)
1.2.19 URB597
Storr 2008 URB597 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
1.2.20 AM1241
Storr 2009 AM1241 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
1.2.21 JWH133
Storr 2009 JWH133 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)
1.2.22 THC
Jamontt 2010 THC 10mg/kg i.p. TNBS (p)
Jamontt 2010 THC 20mg/kg i.p. TNBS (p)
Jamontt 2010 THC 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 4.11; Chi² = 9.99, df = 2 (P = 0.007); I² = 80%
Test for overall effect: Z = 1.07 (P = 0.28)
1.2.24 αβ Amyrin
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (p)
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Heterogeneity: Tau² = 0.66; Chi² = 139.42, df = 56 (P < 0.00001); I² = 60%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Chi² = 38.51, df = 20 (P = 0.008), I² = 48.1%
Mean
40.91
7.8
34.4
39.19
11.9
43.14
116.4
44.5
77.85
85.7
116.04
0.4438
0.68
0.69
0.615
6.279
47.2
45.3
32.8
24.4
786
35.2
16
17.2
16.15
18.43
27.14
44.9
5.7
4.62
5.7
2.87
4.6
69.4
60.03
80.5
70.83
4.1
5.5
2.9
1.74
33.14
61.01
86.36
142
21.98
67.06
313.5
172
30.5
32.9
25
1.74
2.21
4.37
0.16
0.43
SD
6.7357
1.4207
5.6
28.14
2.9394
33.2039
84.3379
39.802
37.7895
56.1253
102.1062
0.208
0.2012
1.5652
2.9069
3.1752
23.1931
20.9304
19.6774
20.3482
388.9602
19.0066
15.4289
9.051
10.748
7.3539
8.8813
27.4357
13.2
0.5814
1.7889
1.3266
0.3317
21.8197
32.5715
17.7088
50.7444
4.9749
3.6483
9.1679
0.4164
7.2001
29.1297
48.1964
35.3553
33.541
16.7705
69.2207
53.1315
6.5054
49.6407
39.0323
0.3648
0.2449
0.9798
0.8944
0.246
Total
10
6
4
4
6
10
10
50
5
5
5
8
23
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
8
8
8
8
32
9
9
5
5
11
11
10
10
10
11
11
11
95
5
6
11
5
5
7
8
8
23
5
5
10
14
14
28
8
8
5
5
8
8
11
6
6
23
5
5
10
419
Mean
100
17.9
68.69
100
17.9
100
100
100
100
100
100
1.218
1.218
1.218
1.218
68.966
185.25
184.3
100
100
1,428
100
100
100.1
47.45
39.43
47.45
47.45
199
6.06
9.03
6.05
6.05
105.55
100
106.9
101.38
6.05
6.05
100
3.21
67.64
100
100
100
100
100.31
435
428.37
100
100
100
3.33
3.33
3.33
0.719
0.719
SD
9.8284
1.7321
11.2
18.4
1.7321
31.939
26.2469
89.6663
89.66
127.523
127.52
0.246
0.246
0.246
0.246
12.522
62.2254
66.468
89.6663
128.1267
528.1004
31.0813
31.0813
92.7724
14.99
9.8995
14.99
14.99
87.3098
0.5143
0.2236
2.3548
2.3548
43.9557
43.6394
35.1013
18.5731
2.3548
2.3548
103.4489
8.0833
12.9692
24.8701
25.7104
25.4558
46.7338
19.0066
138.4413
344.2325
92.7724
74.4611
94.4695
0.995
0.995
0.995
1.5588
1.5588
Total
10
3
4
4
3
10
10
44
5
5
5
4
19
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
2
8
3
3
16
7
7
5
5
3
3
10
10
10
11
3
2
62
7
6
13
5
5
7
8
8
23
5
5
10
14
14
28
8
8
5
5
8
8
2
2
2
6
3
2
5
338
Weight
0.9%
0.5%
0.8%
1.2%
1.4%
2.2%
2.5%
9.5%
1.9%
2.0%
2.0%
2.0%
7.9%
1.2%
1.5%
2.0%
2.0%
6.6%
0.5%
0.5%
1.7%
1.8%
1.9%
1.9%
7.3%
2.3%
2.3%
1.4%
1.4%
1.1%
2.2%
3.3%
1.2%
1.9%
1.6%
1.9%
6.5%
1.6%
1.6%
1.4%
1.4%
1.7%
1.8%
2.4%
2.4%
2.4%
2.5%
1.9%
1.7%
19.5%
2.0%
2.1%
4.1%
1.2%
1.2%
2.0%
2.3%
2.2%
6.5%
1.6%
1.6%
3.3%
2.6%
2.6%
5.1%
2.2%
2.2%
1.9%
1.9%
2.2%
2.2%
1.2%
1.1%
1.5%
3.8%
1.7%
1.5%
3.3%
100.0%
IV, Random, 95% CI
-6.72 [-9.20, -4.23]
-5.92 [-9.82, -2.02]
-3.37 [-6.07, -0.67]
-2.22 [-4.29, -0.16]
-2.01 [-3.87, -0.15]
-1.67 [-2.72, -0.62]
0.25 [-0.63, 1.13]
-2.74 [-4.42, -1.06]
-0.72 [-2.03, 0.58]
-0.29 [-1.54, 0.96]
-0.13 [-1.37, 1.11]
0.13 [-1.07, 1.34]
-0.23 [-0.86, 0.39]
-3.07 [-5.20, -0.94]
-2.16 [-3.90, -0.42]
-0.43 [-1.69, 0.84]
-0.26 [-1.51, 0.98]
-1.26 [-2.48, -0.05]
-6.20 [-9.90, -2.50]
-6.20 [-9.90, -2.50]
-2.78 [-4.26, -1.30]
-2.67 [-4.11, -1.22]
-0.94 [-2.28, 0.41]
-0.74 [-2.05, 0.56]
-1.74 [-2.81, -0.67]
-1.33 [-2.31, -0.34]
-1.33 [-2.31, -0.34]
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Figure 5. Forest plot of the effects of cannabinoid treatment on MPO activity subdivided by drug type. Time of administration in relation to onset of colitis 
is given where 'p' represents prophylactic administration, and 't' represents therapeutic administration. 
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Figure 6.  The effect of cannabinoid treatment on experimentally induced colitis determined by DAI (A) 
and MPO (B) predicted by timing of drug administration in relation to colitis onset. The effect of study 
quality, determined by mSTAIR score and SYRCLE score, on effect size in DAI (C, E) and MPO (D, F). 
Study weights are represented by the diameter of the circle, with larger circles representing studies with 
largest weight in the analysis.       
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Figure 7.  Funnel plots evaluating for publication bias in (A) MPO activity and (B) DAI.  Standard error of 
the standardized mean difference (SE (SMD), y axes) for each study is plotted against its effect size 
(SMD, x axes). 
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Cannabinoid class   Drug Description 
   
Endocannabinoids   
 AEA Anandamide 
 PEA Palmitoylethanolamide 
 uPEA Ultramicronised PEA 
Phytocannabinoids   
 Cannabis sativa  Multiple compounds 
 CBC Cannibichromene 
 CBD Cannabidiol 
 CBG Cannabigerol 
 CBN Cannabinol 
 THC Tetrahydrocannabinol 
   
Cannabinomimetics   
 αβ Amyrin CB1 and CB2 agonist 
 ACEA Arachidonyl-2'-chloroethylamide 
 Adelmidrol PEA analogue 
 AM1241 CB2 full agonist, partial CB1 agonist 
 AM841 Peripherally restricted CB1 agonist 
 βCaryophyllene CB2 agonist 
 CID16020046 GPR55 inverse agonist 
 Compound 26 CB2 agonist 
 CP55,940 CB1 and CB2 agonist 
 HU210 THC analogue 
 HU308 CB2 agonist 
 JWH015 CB2 full agonist, weak CB1 agonist 
 JHW133 CB2 full agonist, weak CB1 agonist 
 O-1602 GPR18 and GPR55 agonist 
 SAB378 Peripherally restricted CB1 and CB2 agonist 
 WIN55,212-2 CB1 full agonist 
Enzyme Inhibitors   
 AA5HT FAAH inhibitor 
 AM3506 FAAH inhibitor 
 AM9053 NAAA inhibitor 
 ARN2508 FAAH inhibitor 
 compound 39 FAAH inhibitor 
 JZL184 MAGL inhibitor 
 PF-3845 FAAH inhibitor 
 URB597 FAAH inhibitor 
Reuptake inhibitors   
 VDM11 AEA reuptake inhibitor 
Table 1 – Cannabinoid drugs found by search strategy. 
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Study Species Model Compound Route/dosage Time of 
administration 
verses 
inflammation 
Time of 
assessment post 
inflammation 
Modified 
STAIR 
score 
SRCYCLE 
Score 
Capasso 2001 
(32) 
ICR mice CO PEA i.p 2.5-30 mg/kg 20 minutes pre 4 days  4 1 
Izzo 2001 (9) ICR mice CO CP 55,940 
Cannabinol  
i.p. 0.03–10 nmol/m  
i.p. 10–3000nmol/m  
4 days post  20 minutes  3 0 
Massa 2004 
(25) 
C57BL/6N 
mice 
DNBS  SR141716 
HU210  
i.p. 3mg/kg  
i.p. 0.05 mg/kg 
Pre, 24 and 48 hours 
post  
3 & 7 days  4 2 
Mathison 2004 
(50) 
Spr-Dawley rats LPS ACEA  
JWH133 
i.p. 1mg/kg 
i.p. 1mg/kg 
70 minutes post  120 minutes  
 
5 0 
D’Argenio 
2006 (22) 
C57/BJ mice   
Wistar rats 
DNBS  
TNBS 
VDM11  
AA-5-HT 
s.c. 5mg/kg 
s.c. 10mg/kg  
Post  3 & 7 days  6 0 
Kimball 2006 
(51) 
CD-1 mice OM ACEA  
JWH133  
i.p. 10mg/kg  
i.p. 2.5mg/kg 
24 hours pre 3 days 3 1 
Capasso 2008 
(52) 
ICR mice CO CBD  
JWH015 
i.p. 5mg/kg 
i.p. 10mg/kg 
20 minutes pre Ach 4 days 5 0 
Engel 2008 (53) AKR mice  TNBS AEA i.p. 5mg/kg 30 minutes pre  3 days  3 1 
Storr 2008 (54) C57/BL mice TNBS URB597 
VDM11 
i.p. 5mg/kg  
i.p.5mg/kg 
30 minutes pre or 24 
hours post  
3 days  4 1 
Borelli 2009 
(46) 
ICR mice DNBS CBD  i.p. 1, 2, 5, 10mg/kg 24 hours post  3 days 3 0 
Li 2009 (55) Rats  
Mice  
LPS HU210  
JWH133  
AM630 
AM251 
100 μg.kg 
 
100 μg.kg    
3 mg/kg 
5 minutes 30 minutes 8 1 
Storr 2009 (56) C57/BL mice TNBS 
DSS 
JWH133  
AM1241  
AM630  
i.p. 20mg/kg  
i.p. 10-20 mg/kg 
i.p. 10mg/kg 
30 minutes pre or 24 
hours post  
1, 3, 5, 7 days 7 1 
Cassol Jr 2010 
(47) 
Wistar rats CLP CBD i.p. 2.5, 4, 10mg/kg Simultaneous 9 days 8 2 
Cluny 2010 
(57) 
C57/BL mice DSS  
TNBS 
SAB378  
AM251  
AM630 
WIN55,212-2                  
i.p 0.1 or 1.0mg/kg  
i.p 1.0mg/kg  
i.p 1.0mg/kg  
i.p 1, 2mg/kg 
4 days post  8 days  5 1 
Kimball 2010 
(58) 
CD1 mice OM ACEA  
JWH133  
i.p. 1mg/kg  
i.p. 1mg/kg 
30 minutes pre  28 days 4 3 
Jamontt 2010 
(45) 
Wistar rats TNBS THC  
CBD 
i.p. 5-20mg/kg 
i.p. 5-20mg/kg  
30 minutes pre  3 days 5 1 
Alhouayek 
2011 (59) 
C57BL/6 mice  TNBS JZL184  i.p. 16mg/kg Pre onset 3 days  2 1 
Andrejak 2011 
(60) 
C57/BL mice TNBS Compound 39  i.p. 5mg/kg 3 days pre  3 days  6 1 
Bento 2011 
(61) 
CD1 mice DSS βCaryophyllene  i.p. 12.5, 25, 
50mg/kg 
3 -7 days post  7 days  4 1 
Defilipis 2011  
(49) 
OF1 mice 
 
LPS 
 
CBD i.p. 10mg/kg 
 
6 hours post  120 minutes  6 1 
Lin 2011 (43) C57/BL mice 
Spr-Dawley rats 
LPS CBD  
O-1602  
i.p. 10mg/kg 
I.p. 1mg/kg 
30 minutes pre 20 minutes 5 1 
Schicho 2011 
(62) 
C57/BL mice DSS  
TNBS 
O-1602  i.p. 5mg/kg 30 minutes pre  7 days  3 3 
Bashashati 
2012 (63) 
CD1 mice LPS AM3506  i.p. 100ug.kg 20 minutes pre  120 minutes  3 0 
Izzo 2012 (64) ICR mice CO CBC i.p. 15mg/kg 20 minutes pre exam 4 days  5 2 
Lehmann 2012 
(65) 
Lewis rats LPS  
CASP  
HU308  2.5mg/kg 15 minutes post  2 – 16 hours  4 0 
Schicho 2012 
(42) 
C57/BL mice TNBS CBD i.p. 10mg/kg  
p.o. 20mg/kg  
p.r. 20mg/kg 
30 minutes pre onset 7 days 4 0 
Singh 2012 (66) C57/BL mice IL-10 -/- 
DSS 
JWH133 i.p. 2.5mg/kg Simultaneous 7 – 14 days 5 1 
Borrelli 2013 
(67) 
ICR mice  DNBS CBG i.p. 30mg/kg 3 days pre  3 days 5 1 
Esposito 2014 
(33) 
CD-1 mice 
 
DSS PEA 
 
i.p. 10mg/kg 
 
2 days post  
 
7 days  
 
5 2 
Li 2013 (68) C57/BL mice DSS WIN55,212-2  i.p. 5mg/kg Simultaneous 7 days  4 1 
Matos 2013 
(69) 
CD1 mice DSS αβ Amyrin p.o. 1, 3, 10mg/kg Pre and 3 days post  7 days  6 1 
Naftali 2013   
(70) 
Clinical trial Crohns Cannabis sativa 
extract (THC) 
115 mg inhaled N/A 8 weeks NA NA 
Romano 2013 
(71) 
ICR mice DNBS CBC i.p 0.1-1.0mg/kg    24 hours post 3 days  6 0 
Wallace 2013 
(72) 
Wistar rats DNBS C. sativa (MMJ) 
AM630 
i.c. 6 mg/kg  
p.o. 10mg/kg 
30 minutes pre and 
24 hours post  
7 days 4 1 
Borelli 2015 
(73) 
ICR mice DNBS PEA i.p 1mg/kg 
p.o. 1mg/kg 
3 days pre  3 days 5 1 
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Capasso 2014 
(20) 
ICR mice OM PEA i.p. 10mg/kg 30 minutes  3 and 7 days 6 2 
Fichna 2014 
(74) 
CD1 mice DSS  
DNBS 
AM841 
CB13  
i.p. 0.01, 0.1,1 
mg/kg 
i.p. 0.1 mg/kg 
15 minutes pre  3 and 7 days 4 0 
Salaga 2014 
(75) 
C57/BL mice TNBS  
DSS 
PF3845  i.p. 10mg/kg 
p.o. 5mg/kg 
i.c. 5mg/kg 
30 minutes 3 and 7 days 2 0 
Sardinha 2014 
(76) 
C57/BL mice LPS HU308  
AM630  
URB597 
JZL184 
i.v. 2.5mg/kg  
i.v.2.5mg/kg   
i.p. 0.6mg/kg 
i.p. 16mg/kg 
15 minutes pre  Simultaneous 6 0 
Alhouayek 
2015 (77) 
CD57/BL mice TNBS 
DSS 
PEA 
PF-3845 
AM9503 
i.p. 10mg/kg 
i.p. 10mg/kg   
i.p. 10mg/kg 
Simultaneous and 5 
days post  
7 days 4 1 
El bakali 2015 
(78) 
C57/BL mice TNBS Compound 26 p.o. 10mg/kg 2 days pre  7 days 6 0 
Impellizzeri 20
15 (79) 
CD1 mice DNBS uPEA i.p. 10mg/kg 1 hour post  4 days 9 2 
Sasso 2015 (80) CD1 mice TNBS 
DSS 
ARN2508  p.o. 5mg/kg Simultaneous 7 days 8 3 
Stančić 2015 
(81) 
C57/BL mice DSS 
TNBS 
CID16020046  s.c. 20mg/kg   30 minutes  7 days 6 1 
Cordaro 2016 
(82) 
CD1 mice DNBS Adelmidrol  p.o. 10mg/kg 60 minutes post 4 days 4 1 
Feng 2016 (83) C57/BL mice DSS WIN55212-2 i.p. 5mg/kg  Simultaneous and 60 
hours post  
7 days 5 1 
Ke 2016 (84) C57/BL mice DSS HU308  i.p. 1mg/kg Simultaneous and 
daily 
8 days 4 2 
Krohn 2016 
(40) 
CD1 mice TNBS Ab-CBD 
O-1918 
AM251  
AM630 
i.p. 5mg/kg 
i.p. 5mg/kg 
i.p. 5mg/kg 
i.p. 5mg/kg 
45 minutes pre  4 days 6 1 
Pagano 2016 
(39) 
ICR mice DNBS  
CO 
CBD   
Pure CBD 
i.p. 30mg/kg 
p.o. 60mg/kg 
24 hours post  3 days 3 0 
Sarnelli 2016 
(85) 
CD1 mice DSS PEA i.p. 2, 10mg/kg 2 days post  7 days 6 1 
Lin 2017 (86) C57/BL mice DSS HU210  i.p. 0.05mg/kg 30 minutes pre 7 days 5 1 
Shamran 
2017(87) 
C57/BL mice DSS FAAH-II i.p. 5 – 40mg/kg 24 hours post  7 days 6 1 
Naftali 2017 
(35) 
Clinical trial Crohns CBD 10mg p.o. BD N/A 8 weeks NA NA 
CO, croton oil; DNBS, dinitrobenzosulphonic acid; LPS, lipopolysaccharide; TNBS, trinitrobenzosulphonic acid; DSS, dextran sulphate sodium; 
OM, oil of mustard; CASP, colon ascendens stent peritonitis; IL-10, interleukin 10; PEA, palmitoylethanolamide; AEA, anandamide; CBD, 
cannabidiol; THC; tetrahydrocannabinol;  CBC, cannabichromene; CBG, cannabigerol; MMJ, medicinal cannabis; uPEA, ultramicronised PEA, 
AB-CBD, abnormal CBD; FAAH-II, fatty acid aminohydrolase II; i.p. intraperitoneal, i.c. intracolonic, p.o. oral administration; s.c. subcutaneous; 
iv.v intravenous; p.r. per rectum; Ach, acetylcholine.  
 
Table 2. Characteristics of studies included for systematic review. 
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Table 3. The effects of cannabinoids on Disease Activity Score caused by experimental colitis 
grouped by drug 
  
 No. of 
Studies 
No. of 
animals 
SMD [95% CI] p value I2 (%) Clinical 
significance 
Endocannabinoids       
PEA 6 118 -1.45 [-1.94, -0.96] <0.00001 25 High 
AEA 1 12 -3.03 [-4.89, -1.17] 0.001 N/A High 
Phytocannabinoids       
CBD 12 181 -0.56 [-0.97, -0.16] 0.006 29 NS 
THC 3 44 -0.53 [-1.24, 0.17] 0.14 0 NS 
MMJ 1 30 -0.76 [-1.52, -0.00] 0.05 N/A Moderate 
Cannabinomimetics       
αβ Amyrin 4 28 -1.88 [-3.05, -0.72] 0.002 0 High 
AM841 4 36 -1.87 [-3.57, -0.17] 0.03 66 High 
βCaryophyllene 4 40 -1.52 [-2.32, -0.72] 0.0002 6 High 
SAB378 4 56 0.28 [-0.38, 0.94] 0.41 28 NS 
WIN55,212-2 4 60 -1.37 [-1.96, -0.78] <0.00001 0 High 
CID16020046 2 16 -2.24 [-3.94, -0.54] 0.01 17 High 
HU210 2 24 -2.89 [-6.24, 0.46] 0.09 81 NS 
O-1602 2 28 -0.84 [-2.01, 0.33] 0.16 45 NS 
ACEA 1 18 -0.87 [-1.85, 0.11] 0.08 N/A High 
Adelmidrol 1 20 -1.85 [-2.94, -0.77] 0.0008 N/A High 
AM1241 1 12 -3.11 [-5.01, -1.22] 0.001 N/A High 
HU308 1 12 -0.73 [-1.92, 0.45] 0.23 N/A NS 
Enzyme inhibitors       
JWH133 4 53 -2.81 [-4.45, -1.17] 0.0008 71 High 
PF3845 3 48 -2.21 [-3.11, -1.31] <0.00001 25 High 
AA5HT 1 10 -2.16 [-3.90, -0.43] 0.01 N/A High 
ARN2508 1 12 -2.66 [-4.38, -0.93] 0.002 N/A High 
Compound 39 1 20 -1.47 [-2.48, -0.46] 0.004 N/A High 
JZL184 1 22 -1.24 [-2.16, -0.31] 0.009 N/A High 
URB597 1 18 -4.43 [-6.32, -2.55] <0.00001 N/A High 
Transport inhibitors       
VDM115 2 30 -3.06 [-4.21, -1.90] <0.00001 0 High 
Total 68 948 -1.36 [-1.62, -1.09] <0.00001 61 High 
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 No. of 
Studies 
No. of 
animals 
SMD [95% CI] p value I2 (%) Clinical 
significance 
Endocannabinoids       
PEA 7 94 -2.74 [-4.42, -1.06] 0.001 85 High 
Phytocannabinoids       
CBD 10 157 -1.03 [-1.40, -0.66] <0.00001 0 High 
THC 3 29 -1.40 [-3.97, 1.17] 0.28 80 NS 
CBC 1 10 -2.97 [-5.05, -0.89] 0.005 N/A High 
CBG 1 10 -6.20 [-9.90, -2.50] 0.01 N/A High 
Cannabinomimetics       
βCaryophyllene 4 40 -1.26 [-2.48, -0.05] 0.04 60 High 
AM841 4 48 -1.56 [-2.71, -0.41] 0.008 54 High 
SAB378 4 42 -0.23 [-0.86, 0.39] 0.46 0 NS 
WIN55,212-2 4 52 -1.74 [-2.81, -0.67] 0.001 57 High 
αβ Amyrin 2 15 -0.38 [-1.48, 0.71] 0.5 0 NS 
CID16020046 2 56 -1.04 [-1.61, -0.48] 0.0003 0 High 
HU210 2 24 -0.63 [-1.48, 0.23] 0.15 2 NS 
O-1602 2 20 -1.70 [-2.81, -0.60] 0.003 0 High 
ACEA 1 16 -3.15 [-4.75, -1.55] 0.0001 N/A High 
AM1241 1 10 -0.96 [-2.31, 0.39] 0.16 N/A NS 
JWH133 1 16 -0.98 [-2.04, 0.07] 0.09 N/A NS 
Ademidrol 1 20 -1.33 [-2.31, -0.34] 0.009 N/A High 
Enzyme inhibitors       
PF3745 3 46 -0.12 [-1.56, 1.32] 0.81 81 NS 
AA5HT 1 10 -2.27 [-4.05, -0.49] 0.01 N/A High 
URB597 1 16 -1.00 [-2.06, 0.06] 0.06 N/A NS 
Transport inhibitors       
VDM115 2 26 -1.91 [-3.72, -0.10] 0.04 59 High 
Total 57 757 -1.26 [-1.54, -0.97] <0.00001 48.1 High 
Table 4. The effects of cannabinoids on MPO activity caused by experimental colitis grouped by drug 
 
 39 
 
 
PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  6 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
6-7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
6-7 
 40 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
7 
 
 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
8+19 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
8-11+28-
29 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  11 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
30-31 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-11 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  12 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  11 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
13 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
17 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  13-17 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
1 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
 
 1 
The use of cannabinoids in colitis: a systematic review and meta-
analysis 
DG Couch, H Maudslay, B Doleman, J N Lund, SE O’Sullivan 
School of Medicine, Royal Derby Hospital, University of Nottingham, Nottingham, United Kingdom 
Correspondence: Daniel Couch, School of Medicine, Royal Derby Hospital, University of Nottingham, 
Derby. DE22 3DT UK  
E-mail: Couch27@gmail.com  
Phone: 01332724701 
No disclosures. No funding was recived for this study. 
Author contributions: 
Conception and design of the study; Couch DG, Lund J, O’Sullivan SE conceived and designed the 
study 
D Couch and H Maudslay collected data.   
D Couch, H Maudslay, B Doleman, J Lund and S O’Sullivan analysed data. 
D Couch, J Lund and S O’Sullivan were responsible for overall content of the article.   
Drafting or revision of the manuscript; all 
Approval of the final version of the manuscript: all 
 
Keywords: cannabinoid inflammation gut intestine colitis 
  
Main Document
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
Abstract  
Background:Clinical trials investigating the use of cannabinoid drugs for the treatment of intestinal 
inflammation are anticipated secondary to preclinical literature demonstrating efficacy in reducing 
inflammation.   
Methods:We systematically reviewed publications on the benefit of drugs targeting the endo-
cannabinoid system in intestinal inflammation.  We collated studies examining outcomes for meta-
analysis from EMBASE, MEDLINE and Pubmed until March 2017.  Quality was assessed according 
to mSTAIR and SRYCLE score. 
Results:From 2008 papers, 51 publications examining the effect of cannabinoid compounds on 
murine colitis, and two clinical studies were identified. 24 compounds were assessed across 71 
endpoints. Cannabidiol, a phytocannabinoid, was the most investigated drug. Macroscopic colitis 
severity (disease activity index - DAI) and myeloperoxidase activity (MPO) were assessed throughout 
publications and were meta-analysed using random effects models.  Cannabinoids reduced DAI in 
comparison with vehicle; SMD -1.36, 95% CI -1.62 to-1.09, I2=61%).  FAAH inhibitor URB597 had 
the largest effect size (SMD-4.43, 95% CI-6.32,-2.55), followed by the synthetic drug AM1241 (SMD 
–3.11, 95% CI -5.01, -1.22) and the endocannabinoid anandamide (SMD-3.03, 95% CI -4.89,-1.17, I2 
not assessed).  Cannabinoids reduced MPO in rodents compared to vehicle; SMD -1.26, 95% CI-1.54 
to -0.97, I2=48.1%.  Cannabigerol had the largest effect size (SMD -6.20, 95%CI-9.90, -2.50), 
followed by the synthetic CB1 agonist ACEA(SMD -3.15, 95%CI-4.75, -1.55) and synthetic CB1/2 
agonist WIN55,212-2(SMD-1.74, 95%CI-2.81, -0.67, I2=57%).  We found no evidence of reporting 
bias. No significant difference was found between the prophylactic and therapeutic use of cannabinoid 
drugs.  
Conclusions:There is abundant pre-clinical literature demonstrating the anti-inflammatory effects of 
cannabinoid drugs in inflammation of the gut. Larger randomised controlled-trials are warranted.  
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Table of abbreviations 
PPAR - Peroxisome Proliferator Activating Receptor 
TRPV1 - Transient receptor potential vanilloid 1 
AEA - Anandamide 
2-AG - 2-arachidonoyl glycerol 
PEA - Palmitoylethanolamide 
DNBS - Dinitrobenzene sulphonic acid 
OM - Oil of mustard 
TNBS - Trinitrobenzene sulphonic acid 
DSS - Dextran sulphate sodium 
CO - Croton oil 
THC - Δ9-Tetrahydrocannabinol 
CBD - Cannabidiol 
Ab-CBD - Abnormal cannabidiol 
CBG - Cannabigerol 
CBN - Cannabinol 
MMJ - Medicinal cannabis 
MPO - Myeloperoxidase 
DAI - Disease activity index 
IL-10 - Interleukin-10 
SMD - Standard mean difference 
CI - Confidence interval 
I.c. - Intracolonic 
p.o.- Oral  
i.v. - Intravenous 
p.r. - Per rectum 
s.c. - Subcutaneous  
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Introduction 
Inflammatory bowel disease (IBD) affects 200 per 100,000 adults in the United States and 400 per 
100,000 in the UK (1,2).  Major subtypes consist of Crohns disease and ulcerative colitis.  A 
definitive clinical treatment for these chronic relapsing diseases remains elusive, as currently no 
therapy exists to reverse the clinical pathology without a risk of significant side effects.  5-ASA 
agents, corticosteroids, anti-TNFα antibodies and other immunomodulatory drugs have all been 
shown to induce significant remission in IBD, but are associated with bone marrow suppression, 
opportunistic infection, infusion reactions and malignancy secondary to immunosuppression (3–5).  
The endocannabinoid system (ECS), consisting of multiple receptors and endogenous ligands, 
controls multiple homeostatic processes including gastrointestinal motility, hunger, perception of pain 
and immunity (6–10).  The receptors of the ECS consist of the classical CB1 and CB2 receptors, but 
also the orphan GPR55 receptor, peroxisome proliferator-activated receptors (PPARs) and transient 
receptor potential receptor vanilloid (TRPV) receptors.  These targets are all found on the cells of gut 
mucosa, submucosa, enteric nervous and immune systems.  Endocannabinoids, such as anandamide 
(AEA) and 2-arachiodoylglycerol (2-AG), are intercellular lipid signalling molecules derived on 
demand from membrane precursors (11). They are metabolised by fatty acid amide hydrolase (FAAH) 
as well as N-acyl ethanolamine-hydrolysing acid amidase (NAAA) in the case of AEA, and 
monoacylglycerol lipase (MAGL) in the case of 2-AG (12–14).   Palmitoylethanolamide (PEA), also 
metabolised by NAAA, has been shown to activate PPARα and may increase local concentrations of 
AEA or the affinity of AEA to the CB1 receptor and is therefore included as an atypical cannabinoid 
(15,16).  Phytocannabinoids include Δ-9 tetrahydrocannabinol (THC), cannabidiol (CBD), 
cannabigerol (CBG), cannibichromene (CBC) and up to 60 others and are isolated from Cannabis 
Sativa (11).  THC and CBD have found place in clinical practice in the treatment of childhood 
epilepsy and muscular spasticity in multiple sclerosis (17,18).  A growing collection of synthetic 
cannabinoid agonists have been derived possessing selective high affinity for the CB1, CB2, GPR55 
and TRPV1 receptors, and have been investigated pre-clinically for roles in gut motility, satiety and 
immunity (8). 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 5 
Under inflammatory conditions CB1, CB2 and both PPARα and PPARγ expression increases on the 
submucosa and on adjacent immune cells, whereas GPR55 and TRPV1 expression decreases on the 
mucosa, but increases on enteric nervous tissue (19–21).  Levels of AEA, 2-AG and PEA are 
upregulated in vitro, and also in animal in vivo and human ex-vivo models of intestinal inflammation 
(22–24).  Early experimentation in murine models demonstrated cannabinoids prevent the onset of 
experimental murine colitis or reduced its severity (25).  Since these initial findings, many reports, 
including clinical trials, have now investigated the effect of cannabinoid ligands, or the effect of 
blockade of their metabolising enzymes, on inflammation of the gut.   
There is a significant amount of promising preclinical evidence for the use of cannabinoid agents in 
the treatment of colitis.  Within this study we aimed to gather all preclinical and clinical evidence for 
the use of these drugs in colitis, and where possible, perform meta-analyses across studies in order to 
assess the efficacy of cannabinoids for further clinical trials.  Where possible clinically relevant 
experimental endpoints were assessed.  
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Methods 
Search Strategy 
All studies evaluating the effect of cannabinoid drugs on inflammation of the colon were searched 
from March 1980 until March 2017 by two independent researchers in Medline, EMBASE and 
Pubmed.  Keywords included cannabidiol, tetrahydrocannabinol, anandamide, 2-AG, 
cannibichromene, cannabigerol, cannabinoid, cannabis sativa, colon, intestine, gut, inflammation, 
Crohns, ulcerative and colitis.  Names of synthetic cannabinoid agents were also included.  
References from included studies were searched by hand.  Pre-specified inclusion and exclusion 
criteria were used to prevent bias.  Experiments must have been be performed in the context of 
administration of cannabinoid drugs to inflammatory states of the colon in humans or animals, either 
experimental or due to endogenous disease (Crohns disease or ulcerative colitis).  In vitro studies or 
studies not examining the effect of cannabinoids in intestinal inflammation specifically, or studies 
using cannabinoid antagonists as a primary agent were excluded. A PRISMA checklist is included in 
the appendix. 
Data Acquisition 
The mode of colitis induction in preclinical studies was recorded in addition to the timing of 
cannabinoid application.  For the purposes of meta-analysis, data on the macroscopic or histological 
disease scores (disease activity index – DAI) and myeloperoxidase (MPO) activity were collected.  If 
the exact number of animals was not available, the lowest number of animals within the range given 
were used for the experimental group, and the highest number used for the control/vehicle group.  
Where studies reported the effects of more than one cannabinoid sharing a single control group for 
comparison, control group numbers were equally distributed between comparisons to avoid unit of 
analysis issues.  WebPlotDigitiser (version 3.11) was used to extract values from figures in published 
articles where no data values were given in the text.   
Quality 
Quality of included studies were assessed by two independent researchers to quantify risk of bias 
according to the six-point criteria developed by the Cochrane Collaboration risk of bias tool (26).  In 
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order to assess the quality of preclinical studies, the STAIR and Arrive preclinical assessment tools 
were adapted (27,28).   Each of the below were awarded one point: randomisation, assessor blinding, 
results replicated in a second species, dose-response experiments, results replicated in a second model 
of colitis, n=5 or greater in each group, the use of clinically relevant endpoint to assess response of 
colitis, definitive statement of animal numbers in each group,  a statement regarding the housing of 
animals and a statement describing the location and timing of animal experimentation (i.e. in animal 
housing or a separate cage, time of day etc), giving a highest possible score of 10. 
Data analysis 
Where possible, data were grouped into DAI and MPO activity, and subdivided by species and 
compound.  Data from each group were analysed as forest plots using Cochrane Review Manager 
Software (Review Manager 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014), and as funnel plots using Stat (Stat Corp. 2009 Stat Statistical Software: Release 
11. College Station, TX, USA).  Funnel plot asymmetry was tested using Egger’s linear regression 
test.  A P value of <0.05 was considered statistically significant.  As differing studies measured MPO 
activity and DAI using various scales, we present effect estimates as standardized mean differences 
(SMD) with 95% confidence intervals (CI). We used the following SMD values to assess results for 
clinical significance: < -0.5 small clinical significance, -0.5 to -0.8 moderate clinical significance and 
>-0.8 high clinical significance. Due to clinical heterogeneity between the various studies, a random-
effects model was used. We assessed statistical heterogeneity using the I2 statistic, with >50% 
regarded as evidence of statistical heterogeneity. We assessed the quality of evidence using the 
previously validated SYRCLE criteria, with studies graded out of 10 (29). Studies were weighted by 
sample size and statistical significance was set at a minimum of p<0.05.   
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Results 
Search results and study characteristics 
The search strategy returned 2008 results from which 199 relevant publications were identified.  From 
these, 53 publications comprising 106 experiments examining 35 compounds met the inclusion 
criteria (figure 1, table 1 and 2).  Thirty four studies were included in the meta-analysis.   
Forty-three publications studied the effects of cannabinoids on experimental murine colitis, 5 in rats, 
and 3 in both mice and rats.  Two clinical trials examined the effect of a cannabinoid (THC and CBD) 
in Crohns disease.  Within animal publications, 43 used caustic agents (Di-nitrobenzine sulphonic 
acid (DNBS), trinitrobenzene sulphonic acid (TNBS), oil of mustard (OM), dextran sulphate sodium 
(DSS) and croton oil (CO)) to induce colitis, 6 used intravenous or topical lipopolysaccharide, 2 
induced colonic inflammation using surgical arterial ligation or puncture of the colon and 1 induced 
colitis with interleukin-10 (IL-10) knock-down and DSS (figure 2A).  Across all publications, 
including clinical trials, 71 endpoints were examined to evaluate the effect of cannabinoid drugs on 
colitis.  Forty-nine publications (89 experiments) examined more than one endpoint.  Of these 
endpoints MPO and DAI were the most consistently used (34 and 26 studies respectively), and were 
therefore selected for meta-analysis. Incidence of endpoints is given in figure 2B.    
The effect of 7 phytocannabinoids were studied across 18 publications; cannabinol (CBN), CBD, 
THC, CBC, CBG, medicinal cannabis (MMJ) and abnormal CBD (Ab-CBD). 4 endocannabinoids 
were studied across 11 publications (PEA, ultramicronized PEA (uPEA), Arachidonyl-2'-
chloroethylamide (ACEA) and AEA), 15 synthetic cannabinoid agonists were studied across 22 
publications (AM841, Adelmidrol , HU210, CP55,940, WIN55,212-2, AM1241, JHW015, JWH133, 
βCaryophyllene, O-1602, HU308, αβ amyrin CID 16020046 compound 26 and SAB378), and 9 
compounds targeting the catabolism or transport of endogenous cannabinoids were studied across 13 
publications (ARN2508, PF-3845, compound 39, JZL184, AA5HT, VDM11, URB597,  AM9053, 
AM3506).  These compounds are delineated by class in table 1.  The degree of positivity or negativity 
of the outcomes of these studies are displayed in figure 2C.   Twenty-three studies investigated 
underlying receptor mechanisms using knock-out (KO) animals or receptor antagonists.   
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Of the 105 experiments comparing cannabinoids with vehicle or placebo, 67 (63.8%) favoured 
cannabinoids, 34 (32.3%) reported no difference, and 4 (3.8%) favoured vehicle.  Mice were used in 
89 experiments (68.5% of which favoured cannabinoids), rats in 14 (71.4% favoured cannabinoids), 
in 4 experiments both mice and rats were used showing no difference between cannabinoids and 
vehicle.  In the two clinical trials, no difference in primary outcome was found between the use of 
THC cigarettes or oral CBD and placebo.  11 of 14 publications (78.6%) using synthetic CB2 receptor 
agonists favoured cannabinoid use over vehicle, and a further 11 of 13 (84.6%) favoured using FAAH 
inhibitors over vehicle.  The outcome of all cannabinoids across publications is given in figure 2C.   
Two clinical trials examining the effect of CBD and THC in Crohns disease were found.  Naftali et al. 
(2013) conducted a placebo controlled study in Crohns disease patients, comparing THC 115mg 
inhaled alone with placebo.  Disease activity was compared between groups by means of validated 
questionnaire (Crohns disease activity index – CDAI) after 8 weeks of treatment.  A non-significant 
reduction in clinical disease remission as defined by the authors was found at the end of the study 
period, however a secondary endpoint of reduction in overall activity scores was found between 
groups (p=0.028).  In a second study, Naftali et al. (2017) compared oral CBD 10 mg p.o. twice daily 
with placebo in Crohns disease, using CDAI in an identical fashion.  No reduction in disease activity 
was detected between groups.  In both studies the authors measured changes in serum C-reactive 
protein (CRP), within both experimental and placebo groups CRP levels were below 5 units per ml at 
the end of the study periods.  Clinically, CRP levels greater than 5 units per ml are considered 
indicative of inflammatory disease.  Within both studies the combination of CBD and THC within a 
single study were not assessed. 
Of the 104 experiments where timing of drug administration of drug was stated, 37 administered 
cannabinoids therapeutically, of which 62.2% favoured cannabinoid treatment.   19 experiments 
administered cannabinoids prophylactically, of which 52.6% favoured cannabinoid treatment.  48 
experiments administered cannabinoids both prophylactically and therapeutically, of which 75% 
favoured cannabinoid treatment versus vehicle.  
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Meta-Analysis 
34 studies reported the same endpoints of disease activity index or myeloperoxidase activity allowing 
for meta-analysis.  Of the remaining studies heterogeneity of endpoints prevented further meta-
analysis. 
Crohns Disease Activity Index (CDAI). 
The use of two phytocannabinoids, THC or CBD, in two human studies were meta-analysed. 
Phytocannabinoid use decreased severity scores in comparison with placebo (mean difference (MD) -
74.97, 95% CI –229, 0.79, I2=75%.  Figure 3).  THC alone had a significant effect on reducing CDAI 
(MD-154.00, 95% CI -2.68.57, -44.43), whereas CBD alone did not (MD +4.00 95% CI -1.5.39, 
+113.39).     
Disease Activity Index (DAI) 
Thirty-four publications examined the effects of 25 cannabinoid drugs across 68 experiments, within 
mouse and rat models (total n = 948, n = 519 experimental vs 429 in control groups).   Cannabinoid 
drugs reduced DAI in comparison with vehicle; SMD -1.36, 95% CI -1.62 to-1.09, I2=61% (figure 4, 
table 3).  On subgroup analysis there was significant difference between drug subtypes (P<0.001).   
DAI was significantly reduced in mice (SMD -1.49, 95% CI -1.77 to -1.22; I2=61%).  Seven 
experiments within one publication examined the effects of cannabinoids on rat colitis (THC and 
CBD, both conducted in a dose response manner), but did not reach significance at any concentration; 
SMD -0.29, 95% CI -0.77 to 0.20, I2=0%.  SMD and confidence intervals for individual drugs on DAI 
are given in table 3.   
The largest effect size in DAI reduction was caused by an enzyme inhibitor: the FAAH inhibitor 
URB597 (SMD-4.43, 95% CI-6.32,-2.55).  The largest effect size of DAI reduction by an 
endocannabinoid was AEA (SMD-3.03, 95% CI -4.89,-1.17), the largest effect size of DAI reduction 
by a phytocannabinoid was CBD (SMD -0.56, 95% CI-0.97, -0.16, I2= 29%), and the largest synthetic 
cannabinoid effect size on DAI was AM1241 (SMD –3.11, 95% CI -5.01, -1.22).  SMD and 
confidence intervals of individual drugs on DAI are given in table 4.   Eighteen of twenty-five drugs 
had a large effect size, one had a moderate effect size, and six had no significant effect on DAI.   
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Myeloperoxidase Activity (MPO) 
Twenty-six publications investigated the effects of 21 cannabinoid drugs on MPO activity throughout 
57 individual experiments (total n = 757, n = 419 in experimental vs 338 in control groups). 
Cannabinoid drugs reduced MPO in comparison with vehicle; SMD -1.26, 95% CI-1.54 to -0.97, 
I2=48.1% (figure 5, table 4). Overall, there was significant heterogeneity between studies and there 
was significant subgroup difference (I2=48.1%, P<0.008).  MPO was significantly reduced in mice 
and rats (SMD -1.28, 95% CI -1.59 to -0.98 I2=61% and -1.06, 95% CI -1.99 to -0.13, I2=56% 
respectively).  
The largest effect size in MPO reduction was caused by the phytocannabinoid CBG (SMD -6.20, 95% 
CI -9.90 to -2.50, I2 not assessed).  The largest effect size by an endocannabinoid was PEA (SMD -
2.74, 95% CI -4.42, -1.06, I2=85%), the largest synthetic cannabinoid effect size on MPO was caused 
by ACEA (SMD -3.15, 95% CI -4.75, -1.55, I2 not assessed), and the largest effect size of any enzyme 
or transport inhibitor was AA5HT (SMD -2.27, 95% CI -4.05, -0.49, I2 not assessed).    SMD and 
confidence intervals of individual drugs on MPO activity are given in table 4.  Thirteen of 21 
cannabinoid drugs had a large clinical effect, the remaining of which had no significant effect on 
MPO. 
Time of administration 
From the 50 publications examining the effect of cannabinoids on murine colitis, 28 studies 
administered cannabinoid agents either simultaneously with colitis onset, or prophylactically.   17 
administered drugs between 15 minutes and 7 days after the onset of colitis.  Additionally 7 studies 
compared the benefit of prophylactic cannabinoid use to therapeutic, but did not find any difference in 
efficacy.  To investigate if timing of drug treatment affected DAI or MPO we compared study size-
weighted effect sizes (dependent variable) with time of administration (covariate) using meta-
regression.   We found that timing of drug administration weakly predicted effect size in reducing 
DAI and MPO, although this was of borderline statistical significance (P=0.09 R2=11% and P=0.055 
R2=41% respectively, figure 6 A and B).   
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Quality and risk of bias 
Of the 53 papers, 21 used randomisation in their design, 7 reported blinding of assessment, 5 
replicated their results in a second species, and 14 replicated their findings in a second model of 
colitis.  50 reported n≥5 in control and experimental groups.  15 publications reported specific 
numbers within groups.  All papers reported a clinically relevant endpoint.  Median study quality 
modified STAIR score was 5 out of 10 (mean 4.9, SD 2.29). Using meta-regression, higher quality 
scores predicted greater reductions in MPO activity (P=0.043 R2=65%, figure 6 D), but not in DAI 
(P=0.98 R2= 35%, Figure 6 C).     
The SYRCLE risk of bias score for each endpoint showed a trend to larger reduction in DAI in studies 
with a larger risk of bias (P=0.084 R2=69%, figure 6 E), but not MPO (P=0.345 R2=8%, figure 6F). 
Publication Bias  
Funnel plots comparing MPO activity and DAI were constructed and analysed statistically for bias.  
The presence of publication bias was not found in either group (MPO; Egger’s statistic P=0.570, 
figure 7A; DAI; Egger’s statistic P=0.274, figure 7B).   
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Discussion 
The aim of this study was to determine the efficacy of cannabinoid drugs in reducing gut 
inflammation to aid the design of further clinical studies.  We found 53 studies that examined this 
effect using endocannabinoids, phytocannabinoids, synthetic cannabinoids, and enzyme and reuptake 
inhibitors across multiple models of murine and human colitis. In both qualitative assessment and 
meta-analysis, these controlled studies demonstrate that the use of cannabinoid drugs are beneficial in 
reducing colonic inflammation in rats and mice, with unclear effects in human subjects.   
In animal studies, cannabinoids were shown to reduce inflammation both qualitatively, and at meta-
analysis. Across experiments included in this review CB2 agonists, FAAH inhibitors and CBD were 
the most widely studied and showed the greatest therapeutic benefit across all endpoints.  Subgroup 
analyses suggested that CBG caused the greatest reduction in MPO activity scores followed by 
synthetic CB1 agonist ACEA. However both agents were only studied within a single publication.  In 
the MPO analysis the most studied drug was CBD, with 157 animals across 7 publications, 
demonstrating a significant effect on MPO activity reduction.  Similarly, within DAI analysis CBD 
was again the most studied single drug including 181 animal across 6 publications.  Although CBD 
demonstrated a significant effect on DAI reduction, the largest reduction in DAI was caused by the 
FAAH antagonist URB597, studied in one publication.  There was statistical heterogeneity in both 
MPO and DAI analyses, which was partially accounted for by subgroup differences.  At meta-
regression, factors leading to subgroup differences were quality, timing and risk of bias. 
Receptor targets were explored in 23 publications using receptor-specific agonists or antagonists, and 
receptor knock-down.  In murine colitis, agonism of the CB1 or CB2 receptor brought about reduction 
in inflammation, and at subgroup analysis use of the synthetic CB1/CB2 agonists acting demonstrated 
the greatest reduction in disease scores and MPO activity.  In addition, agonism of the PPARα, 
GPR55 and GPR18 receptors also reduced inflammation of the colon.  The wide variation in the 
measured inflammatory endpoints across these studies prevented further meta-analysis.  Interestingly 
the use of the peripherally restricted synthetic agonist SAB378, which agonises both CB1 and CB2 
receptors, had no significant effect on either MPO activity or DAI.   This is in contrast to ex vivo 
explant human colonic data, which demonstrated that cannabinoid agonism with AEA or CBD was 
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beneficial in colonic mucosal inflammation, which were peripherally restricted by definition of the 
explant model (30,31).  Izzo et al. (9) found through receptor antagonism that the effect of CBN in 
preventing hypermobility caused by croton oil was mediated by CB1, but not CB2.   PEA was 
investigated by Capasso et al. (20,32) using two models of inflammation-induced hypermotility.  
Using receptor antagonists in both experiments Capasso et al. found that PEA, in an OM model, acted 
through CB1 but not CB2 or PPARα, but in a CO model PEA was still effective, but did not act 
through CB1 or CB2. This suggests that the mechanism by which PEA acts as an anti-inflammatory 
agent was not mediated by a single receptor, but by receptor co-dependence.   ACEA was investigated 
for receptor mechanism in two publications, both of which found ACEA dependent on CB1.  None of 
the reviewed studies investigated a mechanism of action for AEA in gut inflammation, however one 
ex vivo human study from Harvey et al. found that AEA prevented increased cytokine production in 
experimentally inflamed human mucosa was dependent on CB2, although the authors did not report 
antagonism of any other receptor (31).   
The specific mechanism by which manipulation of the cannabinoid system affects inflammation is not 
clear.  Esposito et al. (33) demonstrated that PEA brought about anti-inflammatory effects on enteric 
glial cells acting at toll-like receptor 4, suggesting that rather than acting at an epithelial mucosal 
level, acts at either at innate immune colonies or the enteric nervous system. This hypothesis as 
recently been evidence by a study demonstrating that both CBD and PEA do not act on the immune 
response of epithelial cells, but are likely to require the presence of these other cells types, acting 
through down regulation of NF-κβ (34), but is challenged by Cluny et al, demonstrating that 
peripherally restricted cannabinoids have a diminished effect on inflammation.  Nevertheless it is 
clear that the mechanism of action of cannabinoids does not simply lie at the epithelial level, but is 
likely to reside within the gut-brain axis.  
From the clinical literature we found two randomised placebo-controlled studies examining the effect 
of phytocannabinoids in humans.  Our analysis found no overall effect of THC or CBD on disease 
scores, however there was large statistical and clinical heterogeneity between these studies.  We found 
from meta-analysis that inhaled THC did have a beneficial effect on CDAI at 8 weeks, whereas CBD 
did not.  There may be several reasons for this heterogeneity, firstly in all groups, small cohort sizes 
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were used which may have overestimated positive or negative effects in both studies, making 
meaningful conclusions regarding the use of CBD or THC in inflammatory bowel disease difficult.   
Secondly, within the Naftali et al. (2017) study, very low doses of CBD were utilized compared to the 
use of CBD in other clinical trials, which commonly used 600mg twice daily (35).  A recent trial in 
drug-resistant epilepsy used 20mg.kg-1 daily for 4 weeks, with a small number of participants 
experiencing side effects such as vomiting and diarrhoea (36).  It is likely that in adult males such 
10mg doses had no clinical effect on Crohns disease as insufficient plasma concentrations may have 
been reached due to the poor bioavailability of oral CBD.  A major flaw within the Naftali et al. 2013 
trial is that sham cigarettes contained cannabis sativa flowers in which active cannabinoids had been 
removed.  However, it is unlikely that other compounds present in cannabis (such as terpenes) which 
are known to have an anti-inflammatory effect had also been removed, which may have introduced 
positive bias into the study (37).  However, despite these drawbacks, the Naftali et al. 2013 trial 
demonstrated a significant reduction in pain and the use of steroid therapy, with increased sleep and 
satisfaction levels with THC use compared to placebo.  Although not included in this analysis, a study 
from Storr et al. (38) demonstrated that although cannabis use provided symptomatic relief  from 
Crohns disease, the risk of salvage surgery was increased within 6 months of use (odds ratio = 5.03, 
95% confidence interval = 1.45-17.46).  However these findings have not yet been supported from 
randomised, blinding controlled trials.  We may suggest, therefore, that phytocannabinoid use may be 
a future therapy in intestinal inflammation, although before firm conclusions are drawn, further 
clinical studies examining their effects be conducted at higher, therapeutic dosages with adequately 
powered cohort sizes.  As MMJ use in inflammatory bowel disease has been justified because of its 
effects on appetite and diarrhoea, studies may be designed to examine these quality of life-affecting 
endpoints directly.    
We found that most of the existing cannabinoid-gut research focusses on the therapeutic potential of 
CBD.  This is unsurprising as CBD is currently used clinically, is well tolerated, and has shown 
consistently positive results.  Nine studies found a positive, dose dependent effect on local 
inflammatory cytokine expression, COX2 activation, MPO activity, enteric glial cell activation and 
caspase-3 production, with associated improvements in macroscopic and histologic grades of 
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inflammation (39–46).  One study also showed that intraperitoneal CBD administration decreased 
oxidative-stress scores of peripheral lung and brain tissue following intestinal inflammation (47), 
adding to the existing evidence that CBD maintains the gut barrier during inflammation (48).  Despite 
being the most-studied drug, the mechanism by which CBD acts was not made clear by this review. 
One study by De Fillipis et al (44), found that hyper-motility caused by LPS administration in mice 
was reduced by CBD through a CB1 dependent mechanism.  Similarly, Capasso et al. in 2008 found 
that CBD prevented croton oil-induced hypermotility via CB1.  In vitro, de Fillipis et al. in 2011 
demonstrated that in human explant tissue S100B levels, as a marker of glial cell activation was 
decreased by CBD in a PPARγ dependent mechanism (although other antagonists were not 
investigated) (49).   
The timing of cannabinoid administration correlated with reduction in effect on colitis activity, 
although did not reach statistical significance.  There was a correlation between time of drug 
administration and effect size in both DAI and MPO reduction, with earlier administration of 
cannabinoids drugs producing a greater effect size, suggesting that in clinical trials cannabinoids may 
be used prophylactically and therapeutically. There is promise therefore that compounds targeting the 
endocannabinoid system may be able to not only prevent colonic inflammation, but treat established 
intestinal inflammatory conditions.  As it is not clear if cannabinoids are more effective when treating 
new-onset or established intestinal inflammation, further study designs should investigate this 
endpoint specifically. 
One important potential area for research is the combination of cannabinoid drugs with existing 
treatments for inflammatory bowel disease.  In clinical practice it is common to treat patients with 
acute severe Crohns and ulcerative colitis with combination of agents, such as antibiotic, anti-TNFα, 
and corticosteroid therapy.  One study compared the efficacy of CBD and THC with that of 
sulphasalazine, a 5-ASA, a drug commonly used in clinical practice (45).   Although in this study 
CBD and THC efficacy were comparable to that of sulphasalazine, the authors did not examine for the 
potential additive or subtractive effect of these agents in the context of colitis.   
The findings of this study are limited by several factors typically seen in meta-analyses and systematic 
reviews. We found significant heterogeneity between sub-groups in both DAI and MPO analyses, and 
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suggested that 11% and 41% of this was due to the difference in time of administration in terms of 
changes in DAI and MPO respectively.  Additionally we found a high risk of bias study design, and 
median study quality to be relatively low.  Meta-regression demonstrated these factors significantly 
correlated with study outcomes.  Although we did not analyse for differences between scoring 
systems and mode of colitis, these factors may have also contributed to heterogeneity and influenced 
outcome.  We sought to overcome this variability between scoring systems with random effects 
analysis.  Additionally within this review we have examined the effect of cannabinoid drugs en mass, 
which may have affected the overall outcome of meta-analyses.  It is possible that some articles may 
have not been identified in initial searches, or conference abstracts missed from the search period.  
Lastly, where control groups were compared to multiple experimental groups within the same set of 
experiments variance and SMD may be exaggerated, leading to further bias. 
In conclusion, we have shown in this systematic review and meta-analysis that cannabinoid drugs are 
beneficial in treating experimentally-induced murine models of colitis.  These positive findings 
support the development of further human clinical trials.  Current literature converges on CBD, and in 
order to avoid research bias the effect of all cannabinoid drugs, including the large number of 
currently un-investigated phytocannabinoid drugs, should also be investigated.  
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Figure 2. Positive, negative and neutral outcomes of cannabinoid treatment across modes of 
inflammation (A).  Incidence of endpoints across all experiments comparing cannabinoid treatment 
with control (B). The effect of cannabinoid drugs compared to control across all endpoints expressed 
as primary drug investigated (C). 
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Figure 3.  Forest plot of the effects of cannabinoid treatment on Crohns Disease, assessed by 
reduction in CDAI in human studies. 
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Figure 4. Forest plot of the effects of cannabinoid treatment on Disease Activity Score subdivided by drug type. Time of administration in relation to onset 
of colitis is given where 'p' represents prophylactic administration, and ’t’ represents therapeutic administration. 
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101.38
6.05
6.05
100
3.21
67.64
100
100
100
100
100.31
435
428.37
100
100
100
3.33
3.33
3.33
0.719
0.719
SD
9.8284
1.7321
11.2
18.4
1.7321
31.939
26.2469
89.6663
89.66
127.523
127.52
0.246
0.246
0.246
0.246
12.522
62.2254
66.468
89.6663
128.1267
528.1004
31.0813
31.0813
92.7724
14.99
9.8995
14.99
14.99
87.3098
0.5143
0.2236
2.3548
2.3548
43.9557
43.6394
35.1013
18.5731
2.3548
2.3548
103.4489
8.0833
12.9692
24.8701
25.7104
25.4558
46.7338
19.0066
138.4413
344.2325
92.7724
74.4611
94.4695
0.995
0.995
0.995
1.5588
1.5588
Total
10
3
4
4
3
10
10
44
5
5
5
4
19
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
2
8
3
3
16
7
7
5
5
3
3
10
10
10
11
3
2
62
7
6
13
5
5
7
8
8
23
5
5
10
14
14
28
8
8
5
5
8
8
2
2
2
6
3
2
5
338
Weight
0.9%
0.5%
0.8%
1.2%
1.4%
2.2%
2.5%
9.5%
1.9%
2.0%
2.0%
2.0%
7.9%
1.2%
1.5%
2.0%
2.0%
6.6%
0.5%
0.5%
1.7%
1.8%
1.9%
1.9%
7.3%
2.3%
2.3%
1.4%
1.4%
1.1%
2.2%
3.3%
1.2%
1.9%
1.6%
1.9%
6.5%
1.6%
1.6%
1.4%
1.4%
1.7%
1.8%
2.4%
2.4%
2.4%
2.5%
1.9%
1.7%
19.5%
2.0%
2.1%
4.1%
1.2%
1.2%
2.0%
2.3%
2.2%
6.5%
1.6%
1.6%
3.3%
2.6%
2.6%
5.1%
2.2%
2.2%
1.9%
1.9%
2.2%
2.2%
1.2%
1.1%
1.5%
3.8%
1.7%
1.5%
3.3%
100.0%
IV, Random, 95% CI
-6.72 [-9.20, -4.23]
-5.92 [-9.82, -2.02]
-3.37 [-6.07, -0.67]
-2.22 [-4.29, -0.16]
-2.01 [-3.87, -0.15]
-1.67 [-2.72, -0.62]
0.25 [-0.63, 1.13]
-2.74 [-4.42, -1.06]
-0.72 [-2.03, 0.58]
-0.29 [-1.54, 0.96]
-0.13 [-1.37, 1.11]
0.13 [-1.07, 1.34]
-0.23 [-0.86, 0.39]
-3.07 [-5.20, -0.94]
-2.16 [-3.90, -0.42]
-0.43 [-1.69, 0.84]
-0.26 [-1.51, 0.98]
-1.26 [-2.48, -0.05]
-6.20 [-9.90, -2.50]
-6.20 [-9.90, -2.50]
-2.78 [-4.26, -1.30]
-2.67 [-4.11, -1.22]
-0.94 [-2.28, 0.41]
-0.74 [-2.05, 0.56]
-1.74 [-2.81, -0.67]
-1.33 [-2.31, -0.34]
-1.33 [-2.31, -0.34]
-2.27 [-4.05, -0.49]
-2.27 [-4.05, -0.49]
-3.09 [-5.23, -0.96]
-1.19 [-2.28, -0.10]
-1.91 [-3.72, -0.10]
-2.49 [-4.58, -0.40]
-2.28 [-3.61, -0.94]
-1.76 [-3.37, -0.15]
-0.09 [-1.42, 1.24]
-1.56 [-2.71, -0.41]
-3.15 [-4.75, -1.55]
-3.15 [-4.75, -1.55]
-2.37 [-4.19, -0.55]
-2.36 [-4.18, -0.54]
-1.93 [-3.45, -0.40]
-1.35 [-2.75, 0.06]
-1.00 [-1.94, -0.06]
-0.99 [-1.94, -0.05]
-0.91 [-1.84, 0.02]
-0.77 [-1.64, 0.10]
-0.39 [-1.68, 0.89]
-0.14 [-1.65, 1.36]
-1.03 [-1.40, -0.66]
-1.12 [-2.39, 0.15]
-0.24 [-1.37, 0.90]
-0.63 [-1.48, 0.23]
-2.97 [-5.05, -0.89]
-2.97 [-5.05, -0.89]
-1.35 [-2.55, -0.15]
-0.33 [-1.32, 0.66]
1.29 [0.18, 2.40]
-0.12 [-1.56, 1.32]
-1.73 [-3.31, -0.16]
-1.68 [-3.23, -0.12]
-1.70 [-2.81, -0.60]
-1.08 [-1.88, -0.28]
-1.01 [-1.80, -0.22]
-1.04 [-1.61, -0.48]
-1.00 [-2.06, 0.06]
-1.00 [-2.06, 0.06]
-0.96 [-2.31, 0.39]
-0.96 [-2.31, 0.39]
-0.98 [-2.04, 0.07]
-0.98 [-2.04, 0.07]
-3.22 [-5.33, -1.11]
-2.10 [-4.26, 0.06]
0.92 [-0.80, 2.64]
-1.40 [-3.97, 1.17]
-0.42 [-1.88, 1.04]
-0.33 [-1.99, 1.33]
-0.38 [-1.48, 0.71]
-1.26 [-1.54, -0.97]
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Study or Subgroup
1.2.1 PEA
Impellizzeri 2015 PEA 10mg/kg i.p. DNBS (t)
Esposito 2014 PEA 10mg/kg i.p. DSS (t)
Borrelli 2014 PEA 1mg/kg p.o. DNBS (t)
Borrelli 2014 PEA 1mg/kg i.p. DNBS (t)
Esposito 2014 PEA 2mg/kg i.p. DSS (t)
Alhouayek 2015 PEA 10mg/kg i.p. DSS (p)
Alhouayek 2015 PEA 10mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 3.94; Chi² = 39.60, df = 6 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.2 SAB378
Cluny 2010 SAB378 1mg/kg i.p.TNBS (p)
Cluny 2010 SAB378 0.1mg/kg i.p. TNBS (p)
Cluny 2010 SAB378 1mg/kg i.p. DSS (t)
Cluny 2010 SAB378 0.1mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
1.2.3 βCaryophyllene
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (t)
Bento 2011 βCaryophyllene 12.5mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 25mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.90; Chi² = 7.49, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.04 (P = 0.04)
1.2.4 CBG
Borrelli 2013 CBG 30mg/kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.28 (P = 0.001)
1.2.5 WIN 55212-2
Feng 2016 WIN55,212 5mg/kg i.p. DSS (t)
Li 2013 WIN55212-2 5mg/kg i.p. DSS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. TNBS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.68; Chi² = 7.05, df = 3 (P = 0.07); I² = 57%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.6 Ademidrol
Cordaro 2016 Ademidrol 10mg/kg p.o DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.63 (P = 0.009)
1.2.9 AA5HT
D'Argenio 2006 AA5HT10mg/kg s.c DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.50 (P = 0.01)
1.2.10 VDM115
D'Argenio 2006 VDM11 5mg/kg s.c. DNBS (t)
Storr 2008 VDM11 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.06; Chi² = 2.42, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 2.07 (P = 0.04)
1.2.11 AM841
Fichna 2014 AM841 1mg/kg i.p. DSS (p)
Fichna 2014 AM841 1mg/kg i.p. TNBS (p)
Fichna 2014 AM841 0.1mg/kg i.p. DSS (p)
Fichna 2014 AM841 0.01mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.74; Chi² = 6.57, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 2.66 (P = 0.008)
1.2.12 ACEA
Kimball 2006 ACEA 10 mg/kg i.p.OM (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.86 (P = 0.0001)
1.2.13 CBD
Pagano 2016 CBD 30mg/kg i.p. DNBS (t)
Pagano 2016 CBD 60mg/kg p.o. DNBS (t)
Jamontt 2010 CBD 20mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 10mg/kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.r. TNBS (p)
Krohn 2016 abCBD 5mg/kg i.p. TNBS (t)
Schicho 2012 CBD 10mg.kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.o. TNBS (p)
Jamontt 2010 CBD 15mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.33, df = 9 (P = 0.50); I² = 0%
Test for overall effect: Z = 5.47 (P < 0.00001)
1.2.14 HU210
Massa 2004 HU210 0.05mg/kg i.p. DNBS (p)
Lin 2017 HU210 0.05mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
Test for overall effect: Z = 1.44 (P = 0.15)
1.2.15 CBC
Romano 2013 CBC 1mg.kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.80 (P = 0.005)
1.2.16 PF3745
Salaga 2014 PF3845 5mg/kg p.o.  TNBS (p)
Salaga 2014 PF3845 5mg.kg i.c. TNBS (p)
Salaga 2014 PF3845 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.31; Chi² = 10.40, df = 2 (P = 0.006); I² = 81%
Test for overall effect: Z = 0.16 (P = 0.87)
1.2.17 O-1602
Schicho 2011 O-1602 5mg/kg i.p. TNBS (p)
Schicho 2011 O-1602 5mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)
1.2.18 CID16020046
Stancic 2015 CID16020046 20mg/kg i.p. TNBS (p)
Stancic 2015 CID16020046 20mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.63 (P = 0.0003)
1.2.19 URB597
Storr 2008 URB597 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
1.2.20 AM1241
Storr 2009 AM1241 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
1.2.21 JWH133
Storr 2009 JWH133 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)
1.2.22 THC
Jamontt 2010 THC 10mg/kg i.p. TNBS (p)
Jamontt 2010 THC 20mg/kg i.p. TNBS (p)
Jamontt 2010 THC 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 4.11; Chi² = 9.99, df = 2 (P = 0.007); I² = 80%
Test for overall effect: Z = 1.07 (P = 0.28)
1.2.24 αβ Amyrin
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (p)
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Heterogeneity: Tau² = 0.66; Chi² = 139.42, df = 56 (P < 0.00001); I² = 60%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Chi² = 38.51, df = 20 (P = 0.008), I² = 48.1%
Mean
40.91
7.8
34.4
39.19
11.9
43.14
116.4
44.5
77.85
85.7
116.04
0.4438
0.68
0.69
0.615
6.279
47.2
45.3
32.8
24.4
786
35.2
16
17.2
16.15
18.43
27.14
44.9
5.7
4.62
5.7
2.87
4.6
69.4
60.03
80.5
70.83
4.1
5.5
2.9
1.74
33.14
61.01
86.36
142
21.98
67.06
313.5
172
30.5
32.9
25
1.74
2.21
4.37
0.16
0.43
SD
6.7357
1.4207
5.6
28.14
2.9394
33.2039
84.3379
39.802
37.7895
56.1253
102.1062
0.208
0.2012
1.5652
2.9069
3.1752
23.1931
20.9304
19.6774
20.3482
388.9602
19.0066
15.4289
9.051
10.748
7.3539
8.8813
27.4357
13.2
0.5814
1.7889
1.3266
0.3317
21.8197
32.5715
17.7088
50.7444
4.9749
3.6483
9.1679
0.4164
7.2001
29.1297
48.1964
35.3553
33.541
16.7705
69.2207
53.1315
6.5054
49.6407
39.0323
0.3648
0.2449
0.9798
0.8944
0.246
Total
10
6
4
4
6
10
10
50
5
5
5
8
23
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
8
8
8
8
32
9
9
5
5
11
11
10
10
10
11
11
11
95
5
6
11
5
5
7
8
8
23
5
5
10
14
14
28
8
8
5
5
8
8
11
6
6
23
5
5
10
419
Mean
100
17.9
68.69
100
17.9
100
100
100
100
100
100
1.218
1.218
1.218
1.218
68.966
185.25
184.3
100
100
1,428
100
100
100.1
47.45
39.43
47.45
47.45
199
6.06
9.03
6.05
6.05
105.55
100
106.9
101.38
6.05
6.05
100
3.21
67.64
100
100
100
100
100.31
435
428.37
100
100
100
3.33
3.33
3.33
0.719
0.719
SD
9.8284
1.7321
11.2
18.4
1.7321
31.939
26.2469
89.6663
89.66
127.523
127.52
0.246
0.246
0.246
0.246
12.522
62.2254
66.468
89.6663
128.1267
528.1004
31.0813
31.0813
92.7724
14.99
9.8995
14.99
14.99
87.3098
0.5143
0.2236
2.3548
2.3548
43.9557
43.6394
35.1013
18.5731
2.3548
2.3548
103.4489
8.0833
12.9692
24.8701
25.7104
25.4558
46.7338
19.0066
138.4413
344.2325
92.7724
74.4611
94.4695
0.995
0.995
0.995
1.5588
1.5588
Total
10
3
4
4
3
10
10
44
5
5
5
4
19
5
5
5
5
20
5
5
8
8
5
5
26
10
10
5
5
5
8
13
2
8
3
3
16
7
7
5
5
3
3
10
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10
11
3
2
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6
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5
5
7
8
8
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10
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8
5
5
8
8
2
2
2
6
3
2
5
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Weight
0.9%
0.5%
0.8%
1.2%
1.4%
2.2%
2.5%
9.5%
1.9%
2.0%
2.0%
2.0%
7.9%
1.2%
1.5%
2.0%
2.0%
6.6%
0.5%
0.5%
1.7%
1.8%
1.9%
1.9%
7.3%
2.3%
2.3%
1.4%
1.4%
1.1%
2.2%
3.3%
1.2%
1.9%
1.6%
1.9%
6.5%
1.6%
1.6%
1.4%
1.4%
1.7%
1.8%
2.4%
2.4%
2.4%
2.5%
1.9%
1.7%
19.5%
2.0%
2.1%
4.1%
1.2%
1.2%
2.0%
2.3%
2.2%
6.5%
1.6%
1.6%
3.3%
2.6%
2.6%
5.1%
2.2%
2.2%
1.9%
1.9%
2.2%
2.2%
1.2%
1.1%
1.5%
3.8%
1.7%
1.5%
3.3%
100.0%
IV, Random, 95% CI
-6.72 [-9.20, -4.23]
-5.92 [-9.82, -2.02]
-3.37 [-6.07, -0.67]
-2.22 [-4.29, -0.16]
-2.01 [-3.87, -0.15]
-1.67 [-2.72, -0.62]
0.25 [-0.63, 1.13]
-2.74 [-4.42, -1.06]
-0.72 [-2.03, 0.58]
-0.29 [-1.54, 0.96]
-0.13 [-1.37, 1.11]
0.13 [-1.07, 1.34]
-0.23 [-0.86, 0.39]
-3.07 [-5.20, -0.94]
-2.16 [-3.90, -0.42]
-0.43 [-1.69, 0.84]
-0.26 [-1.51, 0.98]
-1.26 [-2.48, -0.05]
-6.20 [-9.90, -2.50]
-6.20 [-9.90, -2.50]
-2.78 [-4.26, -1.30]
-2.67 [-4.11, -1.22]
-0.94 [-2.28, 0.41]
-0.74 [-2.05, 0.56]
-1.74 [-2.81, -0.67]
-1.33 [-2.31, -0.34]
-1.33 [-2.31, -0.34]
-2.27 [-4.05, -0.49]
-2.27 [-4.05, -0.49]
-3.09 [-5.23, -0.96]
-1.19 [-2.28, -0.10]
-1.91 [-3.72, -0.10]
-2.49 [-4.58, -0.40]
-2.28 [-3.61, -0.94]
-1.76 [-3.37, -0.15]
-0.09 [-1.42, 1.24]
-1.56 [-2.71, -0.41]
-3.15 [-4.75, -1.55]
-3.15 [-4.75, -1.55]
-2.37 [-4.19, -0.55]
-2.36 [-4.18, -0.54]
-1.93 [-3.45, -0.40]
-1.35 [-2.75, 0.06]
-1.00 [-1.94, -0.06]
-0.99 [-1.94, -0.05]
-0.91 [-1.84, 0.02]
-0.77 [-1.64, 0.10]
-0.39 [-1.68, 0.89]
-0.14 [-1.65, 1.36]
-1.03 [-1.40, -0.66]
-1.12 [-2.39, 0.15]
-0.24 [-1.37, 0.90]
-0.63 [-1.48, 0.23]
-2.97 [-5.05, -0.89]
-2.97 [-5.05, -0.89]
-1.35 [-2.55, -0.15]
-0.33 [-1.32, 0.66]
1.29 [0.18, 2.40]
-0.12 [-1.56, 1.32]
-1.73 [-3.31, -0.16]
-1.68 [-3.23, -0.12]
-1.70 [-2.81, -0.60]
-1.08 [-1.88, -0.28]
-1.01 [-1.80, -0.22]
-1.04 [-1.61, -0.48]
-1.00 [-2.06, 0.06]
-1.00 [-2.06, 0.06]
-0.96 [-2.31, 0.39]
-0.96 [-2.31, 0.39]
-0.98 [-2.04, 0.07]
-0.98 [-2.04, 0.07]
-3.22 [-5.33, -1.11]
-2.10 [-4.26, 0.06]
0.92 [-0.80, 2.64]
-1.40 [-3.97, 1.17]
-0.42 [-1.88, 1.04]
-0.33 [-1.99, 1.33]
-0.38 [-1.48, 0.71]
-1.26 [-1.54, -0.97]
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Study or Subgroup
1.2.1 PEA
Impellizzeri 2015 PEA 10mg/kg i.p. DNBS (t)
Esposito 2014 PEA 10mg/kg i.p. DSS (t)
Borrelli 2014 PEA 1mg/kg p.o. DNBS (t)
Borrelli 2014 PEA 1mg/kg i.p. DNBS (t)
Esposito 2014 PEA 2mg/kg i.p. DSS (t)
Alhouayek 2015 PEA 10mg/kg i.p. DSS (p)
Alhouayek 2015 PEA 10mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 3.94; Chi² = 39.60, df = 6 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.2 SAB378
Cluny 2010 SAB378 1mg/kg i.p.TNBS (p)
Cluny 2010 SAB378 0.1mg/kg i.p. TNBS (p)
Cluny 2010 SAB378 1mg/kg i.p. DSS (t)
Cluny 2010 SAB378 0.1mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.93, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.74 (P = 0.46)
1.2.3 βCaryophyllene
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 50mg/kg i.p. DSS (t)
Bento 2011 βCaryophyllene 12.5mg/kg i.p. DSS (p)
Bento 2011 βCaryophyllene 25mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.90; Chi² = 7.49, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.04 (P = 0.04)
1.2.4 CBG
Borrelli 2013 CBG 30mg/kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.28 (P = 0.001)
1.2.5 WIN 55212-2
Feng 2016 WIN55,212 5mg/kg i.p. DSS (t)
Li 2013 WIN55212-2 5mg/kg i.p. DSS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. TNBS (t)
Cluny 2010 WIN 52212-2 2mg/kg i.p. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.68; Chi² = 7.05, df = 3 (P = 0.07); I² = 57%
Test for overall effect: Z = 3.20 (P = 0.001)
1.2.6 Ademidrol
Cordaro 2016 Ademidrol 10mg/kg p.o DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.63 (P = 0.009)
1.2.9 AA5HT
D'Argenio 2006 AA5HT10mg/kg s.c DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.50 (P = 0.01)
1.2.10 VDM115
D'Argenio 2006 VDM11 5mg/kg s.c. DNBS (t)
Storr 2008 VDM11 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.06; Chi² = 2.42, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 2.07 (P = 0.04)
1.2.11 AM841
Fichna 2014 AM841 1mg/kg i.p. DSS (p)
Fichna 2014 AM841 1mg/kg i.p. TNBS (p)
Fichna 2014 AM841 0.1mg/kg i.p. DSS (p)
Fichna 2014 AM841 0.01mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.74; Chi² = 6.57, df = 3 (P = 0.09); I² = 54%
Test for overall effect: Z = 2.66 (P = 0.008)
1.2.12 ACEA
Kimball 2006 ACEA 10 mg/kg i.p.OM (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.86 (P = 0.0001)
1.2.13 CBD
Pagano 2016 CBD 30mg/kg i.p. DNBS (t)
Pagano 2016 CBD 60mg/kg p.o. DNBS (t)
Jamontt 2010 CBD 20mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 10mg/kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.r. TNBS (p)
Krohn 2016 abCBD 5mg/kg i.p. TNBS (t)
Schicho 2012 CBD 10mg.kg i.p. TNBS (p)
Schicho 2012 CBD 20mg/kg p.o. TNBS (p)
Jamontt 2010 CBD 15mg/kg i.p. TNBS (p)
Jamontt 2010 CBD 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.33, df = 9 (P = 0.50); I² = 0%
Test for overall effect: Z = 5.47 (P < 0.00001)
1.2.14 HU210
Massa 2004 HU210 0.05mg/kg i.p. DNBS (p)
Lin 2017 HU210 0.05mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
Test for overall effect: Z = 1.44 (P = 0.15)
1.2.15 CBC
Romano 2013 CBC 1mg.kg i.p. DNBS (t)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.80 (P = 0.005)
1.2.16 PF3745
Salaga 2014 PF3845 5mg/kg p.o.  TNBS (p)
Salaga 2014 PF3845 5mg.kg i.c. TNBS (p)
Salaga 2014 PF3845 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.31; Chi² = 10.40, df = 2 (P = 0.006); I² = 81%
Test for overall effect: Z = 0.16 (P = 0.87)
1.2.17 O-1602
Schicho 2011 O-1602 5mg/kg i.p. TNBS (p)
Schicho 2011 O-1602 5mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)
1.2.18 CID16020046
Stancic 2015 CID16020046 20mg/kg i.p. TNBS (p)
Stancic 2015 CID16020046 20mg/kg i.p. DSS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.63 (P = 0.0003)
1.2.19 URB597
Storr 2008 URB597 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
1.2.20 AM1241
Storr 2009 AM1241 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
1.2.21 JWH133
Storr 2009 JWH133 20mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)
1.2.22 THC
Jamontt 2010 THC 10mg/kg i.p. TNBS (p)
Jamontt 2010 THC 20mg/kg i.p. TNBS (p)
Jamontt 2010 THC 5mg/kg i.p. TNBS (p)
Subtotal (95% CI)
Heterogeneity: Tau² = 4.11; Chi² = 9.99, df = 2 (P = 0.007); I² = 80%
Test for overall effect: Z = 1.07 (P = 0.28)
1.2.24 αβ Amyrin
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (p)
Matos 2013 αβAmyrin 10mg/kg p.o. DSS (t)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Heterogeneity: Tau² = 0.66; Chi² = 139.42, df = 56 (P < 0.00001); I² = 60%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Chi² = 38.51, df = 20 (P = 0.008), I² = 48.1%
Mean
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7.8
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39.19
11.9
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116.04
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47.2
45.3
32.8
24.4
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142
21.98
67.06
313.5
172
30.5
32.9
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SD
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Figure 5. Forest plot of the effects of cannabinoid treatment on MPO activity subdivided by drug type. Time of administration in relation to onset of colitis 
is given where 'p' represents prophylactic administration, and 't' represents therapeutic administration. 
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Figure 6.  The effect of cannabinoid treatment on experimentally induced colitis determined by DAI (A) 
and MPO (B) predicted by timing of drug administration in relation to colitis onset. The effect of study 
quality, determined by mSTAIR score and SYRCLE score, on effect size in DAI (C, E) and MPO (D, F). 
Study weights are represented by the diameter of the circle, with larger circles representing studies with 
largest weight in the analysis.       
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Figure 7.  Funnel plots evaluating for publication bias in (A) MPO activity and (B) DAI.  Standard error of 
the standardized mean difference (SE (SMD), y axes) for each study is plotted against its effect size 
(SMD, x axes). 
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Cannabinoid class   Drug Description 
   
Endocannabinoids   
 AEA Anandamide 
 PEA Palmitoylethanolamide 
 uPEA Ultramicronised PEA 
Phytocannabinoids   
 Cannabis sativa  Multiple compounds 
 CBC Cannibichromene 
 CBD Cannabidiol 
 CBG Cannabigerol 
 CBN Cannabinol 
 THC Tetrahydrocannabinol 
   
Cannabinomimetics   
 αβ Amyrin CB1 and CB2 agonist 
 ACEA Arachidonyl-2'-chloroethylamide 
 Adelmidrol PEA analogue 
 AM1241 CB2 full agonist, partial CB1 agonist 
 AM841 Peripherally restricted CB1 agonist 
 βCaryophyllene CB2 agonist 
 CID16020046 GPR55 inverse agonist 
 Compound 26 CB2 agonist 
 CP55,940 CB1 and CB2 agonist 
 HU210 THC analogue 
 HU308 CB2 agonist 
 JWH015 CB2 full agonist, weak CB1 agonist 
 JHW133 CB2 full agonist, weak CB1 agonist 
 O-1602 GPR18 and GPR55 agonist 
 SAB378 Peripherally restricted CB1 and CB2 agonist 
 WIN55,212-2 CB1 full agonist 
Enzyme Inhibitors   
 AA5HT FAAH inhibitor 
 AM3506 FAAH inhibitor 
 AM9053 NAAA inhibitor 
 ARN2508 FAAH inhibitor 
 compound 39 FAAH inhibitor 
 JZL184 MAGL inhibitor 
 PF-3845 FAAH inhibitor 
 URB597 FAAH inhibitor 
Reuptake inhibitors   
 VDM11 AEA reuptake inhibitor 
Table 1 – Cannabinoid drugs found by search strategy. 
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Study Species Model Compound Route/dosage Time of 
administration 
verses 
inflammation 
Time of 
assessment post 
inflammation 
Modified 
STAIR 
score 
SRCYCLE 
Score 
Capasso 2001 
(32) 
ICR mice CO PEA i.p 2.5-30 mg/kg 20 minutes pre 4 days  4 1 
Izzo 2001 (9) ICR mice CO CP 55,940 
Cannabinol  
i.p. 0.03–10 nmol/m  
i.p. 10–3000nmol/m  
4 days post  20 minutes  3 0 
Massa 2004 
(25) 
C57BL/6N 
mice 
DNBS  SR141716 
HU210  
i.p. 3mg/kg  
i.p. 0.05 mg/kg 
Pre, 24 and 48 hours 
post  
3 & 7 days  4 2 
Mathison 2004 
(50) 
Spr-Dawley rats LPS ACEA  
JWH133 
i.p. 1mg/kg 
i.p. 1mg/kg 
70 minutes post  120 minutes  
 
5 0 
D’Argenio 
2006 (22) 
C57/BJ mice   
Wistar rats 
DNBS  
TNBS 
VDM11  
AA-5-HT 
s.c. 5mg/kg 
s.c. 10mg/kg  
Post  3 & 7 days  6 0 
Kimball 2006 
(51) 
CD-1 mice OM ACEA  
JWH133  
i.p. 10mg/kg  
i.p. 2.5mg/kg 
24 hours pre 3 days 3 1 
Capasso 2008 
(52) 
ICR mice CO CBD  
JWH015 
i.p. 5mg/kg 
i.p. 10mg/kg 
20 minutes pre Ach 4 days 5 0 
Engel 2008 (53) AKR mice  TNBS AEA i.p. 5mg/kg 30 minutes pre  3 days  3 1 
Storr 2008 (54) C57/BL mice TNBS URB597 
VDM11 
i.p. 5mg/kg  
i.p.5mg/kg 
30 minutes pre or 24 
hours post  
3 days  4 1 
Borelli 2009 
(46) 
ICR mice DNBS CBD  i.p. 1, 2, 5, 10mg/kg 24 hours post  3 days 3 0 
Li 2009 (55) Rats  
Mice  
LPS HU210  
JWH133  
AM630 
AM251 
100 μg.kg 
 
100 μg.kg    
3 mg/kg 
5 minutes 30 minutes 8 1 
Storr 2009 (56) C57/BL mice TNBS 
DSS 
JWH133  
AM1241  
AM630  
i.p. 20mg/kg  
i.p. 10-20 mg/kg 
i.p. 10mg/kg 
30 minutes pre or 24 
hours post  
1, 3, 5, 7 days 7 1 
Cassol Jr 2010 
(47) 
Wistar rats CLP CBD i.p. 2.5, 4, 10mg/kg Simultaneous 9 days 8 2 
Cluny 2010 
(57) 
C57/BL mice DSS  
TNBS 
SAB378  
AM251  
AM630 
WIN55,212-2                  
i.p 0.1 or 1.0mg/kg  
i.p 1.0mg/kg  
i.p 1.0mg/kg  
i.p 1, 2mg/kg 
4 days post  8 days  5 1 
Kimball 2010 
(58) 
CD1 mice OM ACEA  
JWH133  
i.p. 1mg/kg  
i.p. 1mg/kg 
30 minutes pre  28 days 4 3 
Jamontt 2010 
(45) 
Wistar rats TNBS THC  
CBD 
i.p. 5-20mg/kg 
i.p. 5-20mg/kg  
30 minutes pre  3 days 5 1 
Alhouayek 
2011 (59) 
C57BL/6 mice  TNBS JZL184  i.p. 16mg/kg Pre onset 3 days  2 1 
Andrejak 2011 
(60) 
C57/BL mice TNBS Compound 39  i.p. 5mg/kg 3 days pre  3 days  6 1 
Bento 2011 
(61) 
CD1 mice DSS βCaryophyllene  i.p. 12.5, 25, 
50mg/kg 
3 -7 days post  7 days  4 1 
Defilipis 2011  
(49) 
OF1 mice 
 
LPS 
 
CBD i.p. 10mg/kg 
 
6 hours post  120 minutes  6 1 
Lin 2011 (43) C57/BL mice 
Spr-Dawley rats 
LPS CBD  
O-1602  
i.p. 10mg/kg 
I.p. 1mg/kg 
30 minutes pre 20 minutes 5 1 
Schicho 2011 
(62) 
C57/BL mice DSS  
TNBS 
O-1602  i.p. 5mg/kg 30 minutes pre  7 days  3 3 
Bashashati 
2012 (63) 
CD1 mice LPS AM3506  i.p. 100ug.kg 20 minutes pre  120 minutes  3 0 
Izzo 2012 (64) ICR mice CO CBC i.p. 15mg/kg 20 minutes pre exam 4 days  5 2 
Lehmann 2012 
(65) 
Lewis rats LPS  
CASP  
HU308  2.5mg/kg 15 minutes post  2 – 16 hours  4 0 
Schicho 2012 
(42) 
C57/BL mice TNBS CBD i.p. 10mg/kg  
p.o. 20mg/kg  
p.r. 20mg/kg 
30 minutes pre onset 7 days 4 0 
Singh 2012 (66) C57/BL mice IL-10 -/- 
DSS 
JWH133 i.p. 2.5mg/kg Simultaneous 7 – 14 days 5 1 
Borrelli 2013 
(67) 
ICR mice  DNBS CBG i.p. 30mg/kg 3 days pre  3 days 5 1 
Esposito 2014 
(33) 
CD-1 mice 
 
DSS PEA 
 
i.p. 10mg/kg 
 
2 days post  
 
7 days  
 
5 2 
Li 2013 (68) C57/BL mice DSS WIN55,212-2  i.p. 5mg/kg Simultaneous 7 days  4 1 
Matos 2013 
(69) 
CD1 mice DSS αβ Amyrin p.o. 1, 3, 10mg/kg Pre and 3 days post  7 days  6 1 
Naftali 2013   
(70) 
Clinical trial Crohns Cannabis sativa 
extract (THC) 
115 mg inhaled N/A 8 weeks NA NA 
Romano 2013 
(71) 
ICR mice DNBS CBC i.p 0.1-1.0mg/kg    24 hours post 3 days  6 0 
Wallace 2013 
(72) 
Wistar rats DNBS C. sativa (MMJ) 
AM630 
i.c. 6 mg/kg  
p.o. 10mg/kg 
30 minutes pre and 
24 hours post  
7 days 4 1 
Borelli 2015 
(73) 
ICR mice DNBS PEA i.p 1mg/kg 
p.o. 1mg/kg 
3 days pre  3 days 5 1 
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Capasso 2014 
(20) 
ICR mice OM PEA i.p. 10mg/kg 30 minutes  3 and 7 days 6 2 
Fichna 2014 
(74) 
CD1 mice DSS  
DNBS 
AM841 
CB13  
i.p. 0.01, 0.1,1 
mg/kg 
i.p. 0.1 mg/kg 
15 minutes pre  3 and 7 days 4 0 
Salaga 2014 
(75) 
C57/BL mice TNBS  
DSS 
PF3845  i.p. 10mg/kg 
p.o. 5mg/kg 
i.c. 5mg/kg 
30 minutes 3 and 7 days 2 0 
Sardinha 2014 
(76) 
C57/BL mice LPS HU308  
AM630  
URB597 
JZL184 
i.v. 2.5mg/kg  
i.v.2.5mg/kg   
i.p. 0.6mg/kg 
i.p. 16mg/kg 
15 minutes pre  Simultaneous 6 0 
Alhouayek 
2015 (77) 
CD57/BL mice TNBS 
DSS 
PEA 
PF-3845 
AM9503 
i.p. 10mg/kg 
i.p. 10mg/kg   
i.p. 10mg/kg 
Simultaneous and 5 
days post  
7 days 4 1 
El bakali 2015 
(78) 
C57/BL mice TNBS Compound 26 p.o. 10mg/kg 2 days pre  7 days 6 0 
Impellizzeri 20
15 (79) 
CD1 mice DNBS uPEA i.p. 10mg/kg 1 hour post  4 days 9 2 
Sasso 2015 (80) CD1 mice TNBS 
DSS 
ARN2508  p.o. 5mg/kg Simultaneous 7 days 8 3 
Stančić 2015 
(81) 
C57/BL mice DSS 
TNBS 
CID16020046  s.c. 20mg/kg   30 minutes  7 days 6 1 
Cordaro 2016 
(82) 
CD1 mice DNBS Adelmidrol  p.o. 10mg/kg 60 minutes post 4 days 4 1 
Feng 2016 (83) C57/BL mice DSS WIN55212-2 i.p. 5mg/kg  Simultaneous and 60 
hours post  
7 days 5 1 
Ke 2016 (84) C57/BL mice DSS HU308  i.p. 1mg/kg Simultaneous and 
daily 
8 days 4 2 
Krohn 2016 
(40) 
CD1 mice TNBS Ab-CBD 
O-1918 
AM251  
AM630 
i.p. 5mg/kg 
i.p. 5mg/kg 
i.p. 5mg/kg 
i.p. 5mg/kg 
45 minutes pre  4 days 6 1 
Pagano 2016 
(39) 
ICR mice DNBS  
CO 
CBD   
Pure CBD 
i.p. 30mg/kg 
p.o. 60mg/kg 
24 hours post  3 days 3 0 
Sarnelli 2016 
(85) 
CD1 mice DSS PEA i.p. 2, 10mg/kg 2 days post  7 days 6 1 
Lin 2017 (86) C57/BL mice DSS HU210  i.p. 0.05mg/kg 30 minutes pre 7 days 5 1 
Shamran 
2017(87) 
C57/BL mice DSS FAAH-II i.p. 5 – 40mg/kg 24 hours post  7 days 6 1 
Naftali 2017 
(35) 
Clinical trial Crohns CBD 10mg p.o. BD N/A 8 weeks NA NA 
CO, croton oil; DNBS, dinitrobenzosulphonic acid; LPS, lipopolysaccharide; TNBS, trinitrobenzosulphonic acid; DSS, dextran sulphate sodium; 
OM, oil of mustard; CASP, colon ascendens stent peritonitis; IL-10, interleukin 10; PEA, palmitoylethanolamide; AEA, anandamide; CBD, 
cannabidiol; THC; tetrahydrocannabinol;  CBC, cannabichromene; CBG, cannabigerol; MMJ, medicinal cannabis; uPEA, ultramicronised PEA, 
AB-CBD, abnormal CBD; FAAH-II, fatty acid aminohydrolase II; i.p. intraperitoneal, i.c. intracolonic, p.o. oral administration; s.c. subcutaneous; 
iv.v intravenous; p.r. per rectum; Ach, acetylcholine.  
 
Table 2. Characteristics of studies included for systematic review. 
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Table 3. The effects of cannabinoids on Disease Activity Score caused by experimental colitis 
grouped by drug 
  
 No. of 
Studies 
No. of 
animals 
SMD [95% CI] p value I2 (%) Clinical 
significance 
Endocannabinoids       
PEA 6 118 -1.45 [-1.94, -0.96] <0.00001 25 High 
AEA 1 12 -3.03 [-4.89, -1.17] 0.001 N/A High 
Phytocannabinoids       
CBD 12 181 -0.56 [-0.97, -0.16] 0.006 29 NS 
THC 3 44 -0.53 [-1.24, 0.17] 0.14 0 NS 
MMJ 1 30 -0.76 [-1.52, -0.00] 0.05 N/A Moderate 
Cannabinomimetics       
αβ Amyrin 4 28 -1.88 [-3.05, -0.72] 0.002 0 High 
AM841 4 36 -1.87 [-3.57, -0.17] 0.03 66 High 
βCaryophyllene 4 40 -1.52 [-2.32, -0.72] 0.0002 6 High 
SAB378 4 56 0.28 [-0.38, 0.94] 0.41 28 NS 
WIN55,212-2 4 60 -1.37 [-1.96, -0.78] <0.00001 0 High 
CID16020046 2 16 -2.24 [-3.94, -0.54] 0.01 17 High 
HU210 2 24 -2.89 [-6.24, 0.46] 0.09 81 NS 
O-1602 2 28 -0.84 [-2.01, 0.33] 0.16 45 NS 
ACEA 1 18 -0.87 [-1.85, 0.11] 0.08 N/A High 
Adelmidrol 1 20 -1.85 [-2.94, -0.77] 0.0008 N/A High 
AM1241 1 12 -3.11 [-5.01, -1.22] 0.001 N/A High 
HU308 1 12 -0.73 [-1.92, 0.45] 0.23 N/A NS 
Enzyme inhibitors       
JWH133 4 53 -2.81 [-4.45, -1.17] 0.0008 71 High 
PF3845 3 48 -2.21 [-3.11, -1.31] <0.00001 25 High 
AA5HT 1 10 -2.16 [-3.90, -0.43] 0.01 N/A High 
ARN2508 1 12 -2.66 [-4.38, -0.93] 0.002 N/A High 
Compound 39 1 20 -1.47 [-2.48, -0.46] 0.004 N/A High 
JZL184 1 22 -1.24 [-2.16, -0.31] 0.009 N/A High 
URB597 1 18 -4.43 [-6.32, -2.55] <0.00001 N/A High 
Transport inhibitors       
VDM115 2 30 -3.06 [-4.21, -1.90] <0.00001 0 High 
Total 68 948 -1.36 [-1.62, -1.09] <0.00001 61 High 
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 No. of 
Studies 
No. of 
animals 
SMD [95% CI] p value I2 (%) Clinical 
significance 
Endocannabinoids       
PEA 7 94 -2.74 [-4.42, -1.06] 0.001 85 High 
Phytocannabinoids       
CBD 10 157 -1.03 [-1.40, -0.66] <0.00001 0 High 
THC 3 29 -1.40 [-3.97, 1.17] 0.28 80 NS 
CBC 1 10 -2.97 [-5.05, -0.89] 0.005 N/A High 
CBG 1 10 -6.20 [-9.90, -2.50] 0.01 N/A High 
Cannabinomimetics       
βCaryophyllene 4 40 -1.26 [-2.48, -0.05] 0.04 60 High 
AM841 4 48 -1.56 [-2.71, -0.41] 0.008 54 High 
SAB378 4 42 -0.23 [-0.86, 0.39] 0.46 0 NS 
WIN55,212-2 4 52 -1.74 [-2.81, -0.67] 0.001 57 High 
αβ Amyrin 2 15 -0.38 [-1.48, 0.71] 0.5 0 NS 
CID16020046 2 56 -1.04 [-1.61, -0.48] 0.0003 0 High 
HU210 2 24 -0.63 [-1.48, 0.23] 0.15 2 NS 
O-1602 2 20 -1.70 [-2.81, -0.60] 0.003 0 High 
ACEA 1 16 -3.15 [-4.75, -1.55] 0.0001 N/A High 
AM1241 1 10 -0.96 [-2.31, 0.39] 0.16 N/A NS 
JWH133 1 16 -0.98 [-2.04, 0.07] 0.09 N/A NS 
Ademidrol 1 20 -1.33 [-2.31, -0.34] 0.009 N/A High 
Enzyme inhibitors       
PF3745 3 46 -0.12 [-1.56, 1.32] 0.81 81 NS 
AA5HT 1 10 -2.27 [-4.05, -0.49] 0.01 N/A High 
URB597 1 16 -1.00 [-2.06, 0.06] 0.06 N/A NS 
Transport inhibitors       
VDM115 2 26 -1.91 [-3.72, -0.10] 0.04 59 High 
Total 57 757 -1.26 [-1.54, -0.97] <0.00001 48.1 High 
Table 4. The effects of cannabinoids on MPO activity caused by experimental colitis grouped by drug 
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PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  6 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
6-7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
6-7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
8+19 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
8-11+28-
29 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  11 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
30-31 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-11 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  12 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  11 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
13 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
17 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  13-17 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
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